adriandino的个人主页 - 老虎社区

adriandino

adriandino

暂无个人介绍

IP属地：未知

502关注

10粉丝

4主题

0勋章

2021-04-20

Booster

What to expect at Apple's 'Spring loaded' event

2021-07-23

Buy buy buy

抱歉，原内容已删除

2021-05-07

Up or down?

Think Stocks Will Crash in May? Do These 4 Things Now

2021-04-13

Up down up down.

GameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade

2021-04-27

Good news

AMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?

2021-11-12

Liked

Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch

2021-07-30

Buy buy buy

AMD: Still Growing, Still Undervalued

2021-06-10

Buy buy buy

Global Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022

2021-08-07

Buy buy buy

抱歉，原内容已删除

2021-08-05

Buy buy buy

Here's Why Novavax Stock Soared on Wednesday

2021-10-19

Buy buy buy

Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business

2021-09-28

Buy buy buy

抱歉，原内容已删除

2021-06-07

Buy buy buy

The second-half recovery is underway, and these are the top stocks to own, analysts say

2021-05-21

Buy buy buy

Oatly spikes 25% on its first day of trading

2021-03-31

Buy Buy buy

抱歉，原内容已删除

2021-12-22

Wow

BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody

2021-11-04

Oh no

Moderna stock plunged 9% after reporting quarterly results

2021-06-08

Nice

Biden administration announces plans to strengthen critical supply chains

2021-04-15

Up

Stocks jump at the open as Coinbase rises, Americans go shopping

2021-12-05

Buy

5 Warren Buffett Stocks Are Screaming Buys in December

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3557838603033373","uuid":"3557838603033373","gmtCreate":1594744580157,"gmtModify":1619438267726,"name":"adriandino","pinyin":"adriandino","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":502,"tweetSize":75,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"93.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":"1165830356","repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://ttm.financial/m/news/1165830356?lang=&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 22:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":1874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608690847,"gmtCreate":1638701123059,"gmtModify":1638701123059,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608690847","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","kind":"highlight","pubTimestamp":1638543717,"share":"https://ttm.financial/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b>&nbsp;or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4538":"云计算","BK4504":"桥水持仓","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4507":"流媒体概念","BAC":"美国银行","BRK.B":"伯克希尔B","BK4548":"巴美列捷福持仓","BK4007":"制药","BK4551":"寇图资本持仓","BRK.A":"伯克希尔","BK4207":"综合性银行","BMY":"施贵宝","BK4561":"索罗斯持仓","BK4524":"宅经济概念","BK4557":"大麻股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4527":"明星科技股","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4106":"数据处理与外包服务","AMZN":"亚马逊","BK4503":"景林资产持仓","V":"Visa","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4122":"互联网与直销零售","BK4176":"多领域控股","BK4566":"资本集团","BK4535":"淡马锡持仓"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1,"symbols_score_info":{"AMZN":0.9,"BAC":0.9,"BMY":0.9,"BRK.A":0.9,"BRK.B":0.9,"TEVA":0.9,"V":0.9}},"isVote":1,"tweetType":1,"viewCount":2467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601292988,"gmtCreate":1638531326683,"gmtModify":1638531350519,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Up?","listText":"Up?","text":"Up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601292988","repostId":"1166348149","repostType":4,"repost":{"id":"1166348149","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638522212,"share":"https://ttm.financial/m/news/1166348149?lang=&edition=full","pubTime":"2021-12-03 17:03","market":"us","language":"en","title":"Grab stock rallied 7% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1166348149","media":"Tiger Newspress","summary":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter comple","content":"<p>Grab stock rallied 7% in premarket trading&nbsp;after&nbsp;plunging&nbsp;20% on first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings&nbsp;Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p>\n<p>The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview&nbsp;on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p>\n<p>Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp.&nbsp;and SoftBank Group Corp.'s Vision Fund.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab stock rallied 7% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab stock rallied 7% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-03 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab stock rallied 7% in premarket trading&nbsp;after&nbsp;plunging&nbsp;20% on first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings&nbsp;Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p>\n<p>The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview&nbsp;on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p>\n<p>Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp.&nbsp;and SoftBank Group Corp.'s Vision Fund.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166348149","content_text":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter completing the richest deal yet for a special-purpose acquisition company,Grab Holdings Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.\nThe Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.\nBackers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp. and SoftBank Group Corp.'s Vision Fund.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":2952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879637577,"gmtCreate":1636715008912,"gmtModify":1636715009013,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Liked","listText":"Liked","text":"Liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879637577","repostId":"1149394295","repostType":4,"repost":{"id":"1149394295","kind":"news","pubTimestamp":1636714672,"share":"https://ttm.financial/m/news/1149394295?lang=&edition=full","pubTime":"2021-11-12 18:57","market":"us","language":"en","title":"Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch","url":"https://stock-news.laohu8.com/highlight/detail?id=1149394295","media":"Reuters","summary":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar","content":"<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p>\n<p>Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p>\n<p>The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p>\n<p>It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p>\n<p>Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p>\n<p>On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p>\n<p>He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p>\n<p>Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p>\n<p>According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p>\n<p>\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatura &Co posts $50 mln quarterly profit; plans share buyback, listing switch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTCO":"Natura & Co Holding SA"},"source_url":"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149394295","content_text":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.\nNatura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.\nThe company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.\nIt reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.\nNatura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.\nOn the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.\nHe praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.\nMarques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.\nAccording to Marques, Natura has had a hard time raising prices as key markets deal with these issues.\n\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.","news_type":1,"symbols_score_info":{"NTCO":0.9}},"isVote":1,"tweetType":1,"viewCount":2398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447407,"gmtCreate":1636024166653,"gmtModify":1636024166821,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447407","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://ttm.financial/m/news/1101079537?lang=&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859021205,"gmtCreate":1634641639710,"gmtModify":1634641747081,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859021205","repostId":"1111431743","repostType":4,"repost":{"id":"1111431743","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634637193,"share":"https://ttm.financial/m/news/1111431743?lang=&edition=full","pubTime":"2021-10-19 17:53","market":"us","language":"en","title":"Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business","url":"https://stock-news.laohu8.com/highlight/detail?id=1111431743","media":"Benzinga","summary":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo","content":"<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p>\n<p><b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p>\n<p>The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p>\n<p><b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p>\n<p>Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p>\n<p>The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p>\n<p><b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-19 17:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p>\n<p><b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p>\n<p>The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p>\n<p><b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p>\n<p>Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p>\n<p>The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p>\n<p><b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111431743","content_text":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.\nWhat Happened: The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.\nThe design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.\nWhy It Matters: The semiconductor foray replicates similar moves from rival computing players such as Huawei Technologies and Amazon.com Inc.\nAlibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.\nThe Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.\nPrice Action: Alibaba shares closed 0.68% lower at $166.82 a share on Monday.","news_type":1,"symbols_score_info":{"09988":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":2199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826762189,"gmtCreate":1634055708286,"gmtModify":1634055782125,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826762189","repostId":"1188785088","repostType":4,"repost":{"id":"1188785088","kind":"news","pubTimestamp":1634052465,"share":"https://ttm.financial/m/news/1188785088?lang=&edition=full","pubTime":"2021-10-12 23:27","market":"us","language":"en","title":"Tesla Stock: The Path To $2,500 By 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1188785088","media":"Seeking Alpha","summary":"Summary\n\nTesla experienced explosive gains last year.\nThis year, the stock has struggled, but the co","content":"<p><b>Summary</b></p>\n<ul>\n <li>Tesla experienced explosive gains last year.</li>\n <li>This year, the stock has struggled, but the company is on the right track.</li>\n <li>Better-than-anticipated production and deliveries data suggests the stock can push higher into year-end.</li>\n <li>I suspect Tesla has more upside, and the stock could hit $2,500 in future years.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/207deb1c8eb2af0f4c49abcb18226dd4\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Spencer Platt/Getty Images News</span></p>\n<p>I've been a Tesla(NASDAQ:TSLA)bull for a long time now. It's hard to believe, but the first time I purchased Tesla's stock was eight years ago when the share price was around a split-adjusted $30. Now, roughly 2,500% higher, I am still long Tesla and I think there is more upside in this stock. Tesla remains the leader in the ultra-lucrative EV space. The company arguably has the best products, powered by the most advanced technologies.</p>\n<p>Additionally, Tesla has a unique set of competitive advantages that the company utilizes to stay ahead of its competition year after year. Tesla just put up stellar delivery and production numbers, will likely surpass analysts' expectations this quarter, and the company has enormous revenue and EPS growth potential as we advance. While we will not see Tesla shares gain another 2,500% from here any time soon, the stock can probably hit $1,000 by year-end or early next year. Moreover, Tesla shares could climb substantially higher over the next several years as well.</p>\n<p><b>Technical Setup</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dabe94c8ac775d6a4113df03ad66ffdb\" tg-width=\"640\" tg-height=\"676\" width=\"100%\" height=\"auto\"><span>Source: Stockcharts.com</span></p>\n<p>Tesla had a stellar run-up in 2020 and into year-end last year. Then the stock experienced a significant correction of around 40% down to the $550 level. After this giant pullback, Tesla shares came back for a successful retest of the $550 level. Since then, the stock has been in a steady, concise, upward channel. The current move higher should continue until the bullish trend breaks. However, the bullish trend is robust and could power Tesla shares to $1,000 by the end of this year. Moreover, the company has numerous favorable fundamental factors to go along with the constructive technical setup right now.</p>\n<p><b>Competitive Edge</b></p>\n<p>Tesla continues to enjoy a multifaceted competitive advantage relative to its peers. Its approach to marketing, sales, software development, battery production, supercharging, design, development, and production provides Tesla with a significant edge relative to its competitors. Tesla designs and delivers everything from scratch, and the company remains ever focused on staying ahead of the curve innovation-wise in the EV space. However, most traditional automakers are still mainly focused on ICE vehicles and are still pivoting towards EVs. The bottom line is that the EV market is continuously gaining share over the conventional ICE market, and Tesla is the clear leader when it comes to EVs.</p>\n<p><b>Global EV Market Share First Half of 2021</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/460efe2072a471a917fc24f40e742d6e\" tg-width=\"640\" tg-height=\"497\" width=\"100%\" height=\"auto\"><span>Source: statista.com</span></p>\n<p><b>Deliveries Surge</b></p>\n<p>Tesla just announced another record deliveries quarter of&nbsp;241,300 vehiclesin Q3, a&nbsp;20% increase&nbsp;over the last quarter and a remarkable&nbsp;73% YoY surge. Tesla delivered a total of 9,275 Model S/X vehicles along with 232,025 mainstream Model 3/Y cars. Now, if we adjust for lease vehicles, we arrive at about 7,420 Model S/X vehicle sales and roughly 218,104 Model 3/Y vehicles sold in the third quarter.</p>\n<p>Last quarter (Q2 2021), Tesla sold (leases excluded) a total of about 187,163 vehicles for&nbsp;$9.874 billion. This sales image suggests that the average selling price (\"ASP\") across all vehicles was roughly $53K. Tesla sold approximately 1,550 Model S/X vehicles in Q2. Thus, if we approximate an ASP of $100,000 - $110,000 for Model S/X vehicle sales, we are left with about $52,000 for the Model 3/Y segment.</p>\n<p>Therefore, to get an approximate number for Tesla vehicle sales in Q3, we can use an ASP of $105,000 for the 7,420 Model S/X vehicles sold in the quarter, and we can use the $52,000 ASP for the 218,104 Model 3/Y cars delivered in Q3. This estimate gives us an approximate $800 million in Model S/X sales and $11.34 billion in Model 3/Y sales.</p>\n<p><b>Q3 Earnings Outlook</b></p>\n<p><b>Analysts Estimates:</b></p>\n<p>Last quarter, Tesla delivered&nbsp;$1.45 in EPS, beating consensus analysts' forecasts by about $0.47 or 48%. The company announced revenues of $11.96 billion, beating estimates by $559.33 million simultaneously. Now for Q3, consensus estimates are for EPS of $1.47 and revenues of $13.49 billion. However, I think Tesla will beat these figures as well.</p>\n<p><b>My Estimates:</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49202e7907ab71b56fdc7a9bd908431d\" tg-width=\"640\" tg-height=\"975\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p>\n<p>Instead of the $13.49 billion revenues figure, I am looking for $14.74 billion in revenues, about a 9% increase over consensus expectations. Moreover, I think we can see about $1.85 in non-GAAP EPS out of Tesla in Q3, roughly 26% better than the current consensus figures imply. If Tesla makes good on its notably better-than-expected Q3 results, the stock will have a strong catalyst for a rally into year-end.</p>\n<p><b>Bright Future Ahead for Tesla</b></p>\n<p>Estimates are moving up for Tesla. There have been&nbsp;26 upward revisions&nbsp;relative to just one downward (FY2021) revision over the last 90 days. Still, estimates could continue to move higher.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bda469abb83b22a2a4505ae8d0373158\" tg-width=\"640\" tg-height=\"276\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p>\n<p>First, I want to draw your attention to the number of beats in recent quarters. Sure, Tesla's earnings remain somewhat volatile, but it's difficult to deny the better-than-anticipated earnings growth of late. Consensus estimates were for $3.61 in EPS for the last four quarters. Yet, the company's actual EPS numbers came in at $3.94, an average beat of around 9% over consensus estimates. We already see estimates that are substantial increases on a YoY basis, but I think that results can continue to come in stronger than anticipated (by about 10-20%) as we advance.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8eb9918909984b4de589a4266c10f2a5\" tg-width=\"640\" tg-height=\"282\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3215da27370b6e97c23883ece163f6b\" tg-width=\"640\" tg-height=\"279\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p>\n<p>We see expectations for significant EPS and revenue gains in future years for Tesla. While the stock may seem relatively expensive right now, shares should become increasingly less costly as EPS surge in coming years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4392b7b8eeb3a6fc412f6cd79fe9e44e\" tg-width=\"640\" tg-height=\"330\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p>\n<p>Here is what Tesla's EPS, P/E ratio, and share price could look like in future years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b9e110af6b9747752c5a540bdb00c5a4\" tg-width=\"905\" tg-height=\"382\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p>\n<p><b>The Bottom Line</b></p>\n<p>Tesla's steady and robust EPS growth trend should continue, and I expect the company's share price could reach $2,500 or higher by the end of the decade. Now, some market participants could argue that these stock price projections are optimistic. However, I think that these projections may be relatively modest. First, the company could deliver higher EPS than I anticipate in future years, and second, Tesla's P/E ratio could remain elevated for longer.</p>\n<p>Due to Tesla's unique growth dynamic, the only company that can compare to Tesla is Amazon(NASDAQ:AMZN), in my view. Amazon's current valuation is what a more mature Tesla valuation could become. Incidentally, Amazon currently trades at about 58 times EPS, exactly where I have my 2029 Tesla P/E ratio pegged. Also, the projected stock price appreciation is only 220% from current levels, which is relatively modest if we consider the number of years.</p>\n<p><b>Risks to Tesla's $2,500 Price Target</b></p>\n<p>Of course, when you are talking about Tesla, there are risks to consider. While I estimate that the company can earn close to $50 per share by 2030, the company is very far from such figures right now. Therefore, there is the risk that Tesla will not illustrate the kind of earnings growth I envision. A slowdown in demand, increased competition, supply issues, decreased growth, and other variables are all risks we should consider before betting on Tesla to increase EPS nearly tenfold by 2030. Serious concerns could cause Tesla's valuation to lose altitude, and the company's share price could even head in reverse if any serious issues should arise. Therefore, I believe one should consider the risks carefully before committing any capital to a Tesla investment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock: The Path To $2,500 By 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock: The Path To $2,500 By 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 23:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459378-tesla-path-to-2500-by-2030><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nTesla experienced explosive gains last year.\nThis year, the stock has struggled, but the company is on the right track.\nBetter-than-anticipated production and deliveries data suggests the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4459378-tesla-path-to-2500-by-2030\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://seekingalpha.com/article/4459378-tesla-path-to-2500-by-2030","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188785088","content_text":"Summary\n\nTesla experienced explosive gains last year.\nThis year, the stock has struggled, but the company is on the right track.\nBetter-than-anticipated production and deliveries data suggests the stock can push higher into year-end.\nI suspect Tesla has more upside, and the stock could hit $2,500 in future years.\n\nSpencer Platt/Getty Images News\nI've been a Tesla(NASDAQ:TSLA)bull for a long time now. It's hard to believe, but the first time I purchased Tesla's stock was eight years ago when the share price was around a split-adjusted $30. Now, roughly 2,500% higher, I am still long Tesla and I think there is more upside in this stock. Tesla remains the leader in the ultra-lucrative EV space. The company arguably has the best products, powered by the most advanced technologies.\nAdditionally, Tesla has a unique set of competitive advantages that the company utilizes to stay ahead of its competition year after year. Tesla just put up stellar delivery and production numbers, will likely surpass analysts' expectations this quarter, and the company has enormous revenue and EPS growth potential as we advance. While we will not see Tesla shares gain another 2,500% from here any time soon, the stock can probably hit $1,000 by year-end or early next year. Moreover, Tesla shares could climb substantially higher over the next several years as well.\nTechnical Setup\nSource: Stockcharts.com\nTesla had a stellar run-up in 2020 and into year-end last year. Then the stock experienced a significant correction of around 40% down to the $550 level. After this giant pullback, Tesla shares came back for a successful retest of the $550 level. Since then, the stock has been in a steady, concise, upward channel. The current move higher should continue until the bullish trend breaks. However, the bullish trend is robust and could power Tesla shares to $1,000 by the end of this year. Moreover, the company has numerous favorable fundamental factors to go along with the constructive technical setup right now.\nCompetitive Edge\nTesla continues to enjoy a multifaceted competitive advantage relative to its peers. Its approach to marketing, sales, software development, battery production, supercharging, design, development, and production provides Tesla with a significant edge relative to its competitors. Tesla designs and delivers everything from scratch, and the company remains ever focused on staying ahead of the curve innovation-wise in the EV space. However, most traditional automakers are still mainly focused on ICE vehicles and are still pivoting towards EVs. The bottom line is that the EV market is continuously gaining share over the conventional ICE market, and Tesla is the clear leader when it comes to EVs.\nGlobal EV Market Share First Half of 2021\nSource: statista.com\nDeliveries Surge\nTesla just announced another record deliveries quarter of 241,300 vehiclesin Q3, a 20% increase over the last quarter and a remarkable 73% YoY surge. Tesla delivered a total of 9,275 Model S/X vehicles along with 232,025 mainstream Model 3/Y cars. Now, if we adjust for lease vehicles, we arrive at about 7,420 Model S/X vehicle sales and roughly 218,104 Model 3/Y vehicles sold in the third quarter.\nLast quarter (Q2 2021), Tesla sold (leases excluded) a total of about 187,163 vehicles for $9.874 billion. This sales image suggests that the average selling price (\"ASP\") across all vehicles was roughly $53K. Tesla sold approximately 1,550 Model S/X vehicles in Q2. Thus, if we approximate an ASP of $100,000 - $110,000 for Model S/X vehicle sales, we are left with about $52,000 for the Model 3/Y segment.\nTherefore, to get an approximate number for Tesla vehicle sales in Q3, we can use an ASP of $105,000 for the 7,420 Model S/X vehicles sold in the quarter, and we can use the $52,000 ASP for the 218,104 Model 3/Y cars delivered in Q3. This estimate gives us an approximate $800 million in Model S/X sales and $11.34 billion in Model 3/Y sales.\nQ3 Earnings Outlook\nAnalysts Estimates:\nLast quarter, Tesla delivered $1.45 in EPS, beating consensus analysts' forecasts by about $0.47 or 48%. The company announced revenues of $11.96 billion, beating estimates by $559.33 million simultaneously. Now for Q3, consensus estimates are for EPS of $1.47 and revenues of $13.49 billion. However, I think Tesla will beat these figures as well.\nMy Estimates:\nSource: Author's Material\nInstead of the $13.49 billion revenues figure, I am looking for $14.74 billion in revenues, about a 9% increase over consensus expectations. Moreover, I think we can see about $1.85 in non-GAAP EPS out of Tesla in Q3, roughly 26% better than the current consensus figures imply. If Tesla makes good on its notably better-than-expected Q3 results, the stock will have a strong catalyst for a rally into year-end.\nBright Future Ahead for Tesla\nEstimates are moving up for Tesla. There have been 26 upward revisions relative to just one downward (FY2021) revision over the last 90 days. Still, estimates could continue to move higher.\nSource: seekingalpha.com\nFirst, I want to draw your attention to the number of beats in recent quarters. Sure, Tesla's earnings remain somewhat volatile, but it's difficult to deny the better-than-anticipated earnings growth of late. Consensus estimates were for $3.61 in EPS for the last four quarters. Yet, the company's actual EPS numbers came in at $3.94, an average beat of around 9% over consensus estimates. We already see estimates that are substantial increases on a YoY basis, but I think that results can continue to come in stronger than anticipated (by about 10-20%) as we advance.\nSource: seekingalpha.com\nSource: seekingalpha.com\nWe see expectations for significant EPS and revenue gains in future years for Tesla. While the stock may seem relatively expensive right now, shares should become increasingly less costly as EPS surge in coming years.\nSource: seekingalpha.com\nHere is what Tesla's EPS, P/E ratio, and share price could look like in future years.\nSource: Author's Material\nThe Bottom Line\nTesla's steady and robust EPS growth trend should continue, and I expect the company's share price could reach $2,500 or higher by the end of the decade. Now, some market participants could argue that these stock price projections are optimistic. However, I think that these projections may be relatively modest. First, the company could deliver higher EPS than I anticipate in future years, and second, Tesla's P/E ratio could remain elevated for longer.\nDue to Tesla's unique growth dynamic, the only company that can compare to Tesla is Amazon(NASDAQ:AMZN), in my view. Amazon's current valuation is what a more mature Tesla valuation could become. Incidentally, Amazon currently trades at about 58 times EPS, exactly where I have my 2029 Tesla P/E ratio pegged. Also, the projected stock price appreciation is only 220% from current levels, which is relatively modest if we consider the number of years.\nRisks to Tesla's $2,500 Price Target\nOf course, when you are talking about Tesla, there are risks to consider. While I estimate that the company can earn close to $50 per share by 2030, the company is very far from such figures right now. Therefore, there is the risk that Tesla will not illustrate the kind of earnings growth I envision. A slowdown in demand, increased competition, supply issues, decreased growth, and other variables are all risks we should consider before betting on Tesla to increase EPS nearly tenfold by 2030. Serious concerns could cause Tesla's valuation to lose altitude, and the company's share price could even head in reverse if any serious issues should arise. Therefore, I believe one should consider the risks carefully before committing any capital to a Tesla investment.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828779586,"gmtCreate":1633952916663,"gmtModify":1633952916663,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828779586","repostId":"2174064969","repostType":4,"isVote":1,"tweetType":1,"viewCount":2173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862950901,"gmtCreate":1632832381619,"gmtModify":1632832381719,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862950901","repostId":"2170670597","repostType":4,"repost":{"id":"2170670597","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1632829514,"share":"https://ttm.financial/m/news/2170670597?lang=&edition=full","pubTime":"2021-09-28 19:45","market":"us","language":"en","title":"Tesla set to post strong deliveries after production spurt - analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2170670597","media":"Reuters","summary":"(Reuters) - Wall Street analysts gave upbeat estimates for Tesla's quarterly vehicle deliveries on T","content":"<p>(Reuters) - Wall Street analysts gave upbeat estimates for Tesla's quarterly vehicle deliveries on Tuesday, with <a href=\"https://laohu8.com/S/AONE.U\">one</a> research group predicting it to be the best quarter for the company even as the auto sector wrestles with an unprecedented shortage of parts.</p>\n<p>The electric-car maker had flagged an unusually high end-of-quarter wave of deliveries in a staff memo earlier this month, when Chief Executive Elon Musk asked employees to \"go super hardcore\" to make up for production challenges early in the third quarter.</p>\n<p>Analysts at Piper Sandler and RBC raised their estimates to about 233,000 vehicle deliveries for the third quarter ending Sept. 30, while Credit Suisse's estimate was 225,000-230,000.</p>\n<p>The figures represent a 65%-67% jump from a year earlier. As of Monday, analysts on average expected 222,700 Tesla vehicle deliveries for the third quarter, according to market data provider Visible Alpha data.</p>\n<p>Analysts have also said the impact of the global semiconductor shortage, which has crippled many automakers around the world, may have been smaller on Tesla.</p>\n<p>\"Tesla appears to have been less impacted by the shortage than other (automakers),\" Credit Suisse's Dan Levy said in a report, citing its \"quick pivot\" to new microcontrollers and writing its own vehicle software.</p>\n<p>The third quarter will likely be Tesla's \"strongest\" ever, Piper Sandler's Alexander Potter said, noting increasing adoption of electric vehicles in Europe and China and Tesla's rising market share. Potter has a five-star rating for estimates and recommendations on Tesla, according to Refinitiv Eikon.</p>\n<p>Potter also raised his forecast for annual deliveries to 894,000 from 846,000. That would nearly double last year's deliveries of 499,550.</p>\n<p>China's role as a source of global exports for Tesla is growing, with its Shanghai plant having likely exported about 55,000 vehicles in July-August, up from roughly 30,000 in the second quarter, Credit Suisse's Levy said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla set to post strong deliveries after production spurt - analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla set to post strong deliveries after production spurt - analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-28 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - Wall Street analysts gave upbeat estimates for Tesla's quarterly vehicle deliveries on Tuesday, with <a href=\"https://laohu8.com/S/AONE.U\">one</a> research group predicting it to be the best quarter for the company even as the auto sector wrestles with an unprecedented shortage of parts.</p>\n<p>The electric-car maker had flagged an unusually high end-of-quarter wave of deliveries in a staff memo earlier this month, when Chief Executive Elon Musk asked employees to \"go super hardcore\" to make up for production challenges early in the third quarter.</p>\n<p>Analysts at Piper Sandler and RBC raised their estimates to about 233,000 vehicle deliveries for the third quarter ending Sept. 30, while Credit Suisse's estimate was 225,000-230,000.</p>\n<p>The figures represent a 65%-67% jump from a year earlier. As of Monday, analysts on average expected 222,700 Tesla vehicle deliveries for the third quarter, according to market data provider Visible Alpha data.</p>\n<p>Analysts have also said the impact of the global semiconductor shortage, which has crippled many automakers around the world, may have been smaller on Tesla.</p>\n<p>\"Tesla appears to have been less impacted by the shortage than other (automakers),\" Credit Suisse's Dan Levy said in a report, citing its \"quick pivot\" to new microcontrollers and writing its own vehicle software.</p>\n<p>The third quarter will likely be Tesla's \"strongest\" ever, Piper Sandler's Alexander Potter said, noting increasing adoption of electric vehicles in Europe and China and Tesla's rising market share. Potter has a five-star rating for estimates and recommendations on Tesla, according to Refinitiv Eikon.</p>\n<p>Potter also raised his forecast for annual deliveries to 894,000 from 846,000. That would nearly double last year's deliveries of 499,550.</p>\n<p>China's role as a source of global exports for Tesla is growing, with its Shanghai plant having likely exported about 55,000 vehicles in July-August, up from roughly 30,000 in the second quarter, Credit Suisse's Levy said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170670597","content_text":"(Reuters) - Wall Street analysts gave upbeat estimates for Tesla's quarterly vehicle deliveries on Tuesday, with one research group predicting it to be the best quarter for the company even as the auto sector wrestles with an unprecedented shortage of parts.\nThe electric-car maker had flagged an unusually high end-of-quarter wave of deliveries in a staff memo earlier this month, when Chief Executive Elon Musk asked employees to \"go super hardcore\" to make up for production challenges early in the third quarter.\nAnalysts at Piper Sandler and RBC raised their estimates to about 233,000 vehicle deliveries for the third quarter ending Sept. 30, while Credit Suisse's estimate was 225,000-230,000.\nThe figures represent a 65%-67% jump from a year earlier. As of Monday, analysts on average expected 222,700 Tesla vehicle deliveries for the third quarter, according to market data provider Visible Alpha data.\nAnalysts have also said the impact of the global semiconductor shortage, which has crippled many automakers around the world, may have been smaller on Tesla.\n\"Tesla appears to have been less impacted by the shortage than other (automakers),\" Credit Suisse's Dan Levy said in a report, citing its \"quick pivot\" to new microcontrollers and writing its own vehicle software.\nThe third quarter will likely be Tesla's \"strongest\" ever, Piper Sandler's Alexander Potter said, noting increasing adoption of electric vehicles in Europe and China and Tesla's rising market share. Potter has a five-star rating for estimates and recommendations on Tesla, according to Refinitiv Eikon.\nPotter also raised his forecast for annual deliveries to 894,000 from 846,000. That would nearly double last year's deliveries of 499,550.\nChina's role as a source of global exports for Tesla is growing, with its Shanghai plant having likely exported about 55,000 vehicles in July-August, up from roughly 30,000 in the second quarter, Credit Suisse's Levy said.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866605070,"gmtCreate":1632757990190,"gmtModify":1632798029312,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866605070","repostId":"2170462612","repostType":4,"repost":{"id":"2170462612","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1632755638,"share":"https://ttm.financial/m/news/2170462612?lang=&edition=full","pubTime":"2021-09-27 23:13","market":"us","language":"en","title":"Tesla Shanghai to make 300,000 cars Jan-Sept despite chip shortage -sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2170462612","media":"Reuters","summary":"BEIJING, Sept 26 (Reuters) - Tesla Inc's Shanghai factory is expected to produce 300,000 cars in the","content":"<p>BEIJING, Sept 26 (Reuters) - Tesla Inc's Shanghai factory is expected to produce 300,000 cars in the first nine months of the year, capped by a delivery rush in the end of the July-September quarter, despite a global semiconductor shortage, two sources said.</p>\n<p>The factory makes the electric Model 3 sedans and Model Y sport-utility vehicles for domestic and international markets, including Germany and Japan.</p>\n<p>Around 240,000 vehicles were shipped from the factory in the first eight months, including many for export, according to data from the China Passenger Car Association. Tesla has not announced details on the factory's production.</p>\n<p>The sources requested anonymity, as they were not allowed to speak to media. Tesla did not immediately respond to a request for comment.</p>\n<p>In August, an official in the area where Tesla's factory is located said it is expected to product 450,000 vehicles this year, including 66,100 for export.</p>\n<p>Tesla is hiring managers for legal and external relations teams in China as it faces public scrutiny in the country over data security and customer service complaints. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Shanghai to make 300,000 cars Jan-Sept despite chip shortage -sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Shanghai to make 300,000 cars Jan-Sept despite chip shortage -sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-27 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Sept 26 (Reuters) - Tesla Inc's Shanghai factory is expected to produce 300,000 cars in the first nine months of the year, capped by a delivery rush in the end of the July-September quarter, despite a global semiconductor shortage, two sources said.</p>\n<p>The factory makes the electric Model 3 sedans and Model Y sport-utility vehicles for domestic and international markets, including Germany and Japan.</p>\n<p>Around 240,000 vehicles were shipped from the factory in the first eight months, including many for export, according to data from the China Passenger Car Association. Tesla has not announced details on the factory's production.</p>\n<p>The sources requested anonymity, as they were not allowed to speak to media. Tesla did not immediately respond to a request for comment.</p>\n<p>In August, an official in the area where Tesla's factory is located said it is expected to product 450,000 vehicles this year, including 66,100 for export.</p>\n<p>Tesla is hiring managers for legal and external relations teams in China as it faces public scrutiny in the country over data security and customer service complaints. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170462612","content_text":"BEIJING, Sept 26 (Reuters) - Tesla Inc's Shanghai factory is expected to produce 300,000 cars in the first nine months of the year, capped by a delivery rush in the end of the July-September quarter, despite a global semiconductor shortage, two sources said.\nThe factory makes the electric Model 3 sedans and Model Y sport-utility vehicles for domestic and international markets, including Germany and Japan.\nAround 240,000 vehicles were shipped from the factory in the first eight months, including many for export, according to data from the China Passenger Car Association. Tesla has not announced details on the factory's production.\nThe sources requested anonymity, as they were not allowed to speak to media. Tesla did not immediately respond to a request for comment.\nIn August, an official in the area where Tesla's factory is located said it is expected to product 450,000 vehicles this year, including 66,100 for export.\nTesla is hiring managers for legal and external relations teams in China as it faces public scrutiny in the country over data security and customer service complaints.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869568971,"gmtCreate":1632305103093,"gmtModify":1632801378740,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/869568971","repostId":"2169569506","repostType":4,"repost":{"id":"2169569506","kind":"highlight","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=full","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860484940,"gmtCreate":1632198783280,"gmtModify":1632802111990,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860484940","repostId":"1137903223","repostType":4,"isVote":1,"tweetType":1,"viewCount":400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815859644,"gmtCreate":1630668421188,"gmtModify":1632467838648,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"WOW 🥺","listText":"WOW 🥺","text":"WOW 🥺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815859644","repostId":"2164288879","repostType":4,"isVote":1,"tweetType":1,"viewCount":348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810201389,"gmtCreate":1629977438641,"gmtModify":1633681075879,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810201389","repostId":"1171909968","repostType":4,"repost":{"id":"1171909968","kind":"news","pubTimestamp":1629976999,"share":"https://ttm.financial/m/news/1171909968?lang=&edition=full","pubTime":"2021-08-26 19:23","market":"us","language":"en","title":"Pfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=1171909968","media":"The Wall Street Journal","summary":"Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution ","content":"<p>Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/565070b459fcd837a5c43c1b4a738fa9\" tg-width=\"860\" tg-height=\"573\" width=\"100%\" height=\"auto\"><span>Eurofarma will perform a manufacturing step known as fill-finish for the Pfizer-BioNTech vaccine.</span></p>\n<p>PfizerInc.&nbsp;and&nbsp;BioNTech SE&nbsp;said they are partnering with a Brazilian pharmaceutical company to help manufacture their Covid-19 vaccine in Latin America, which could help meet growing demand for the shot in the region.</p>\n<p>Eurofarma will produce at least 100 million doses annually for distribution in the region, Pfizer and BioNTech said Thursday.</p>\n<p>The doses will be in addition to those reaching Latin America through&nbsp;distribution channels such as Covax, the global initiative intended to get vaccines to low-income countries, and&nbsp;donations by the U.S., the companies said.</p>\n<p>Pfizer and BioNTech said manufacturing will begin next year, after the companies have completed a&nbsp;lengthy process known as technology transfer, in which they provide Eurofarma with top-secret information about the vaccine, manufacturing know-how and other key details.</p>\n<p>The Eurofarma deal is the first in Latin America for the shot from Pfizer and BioNTech, which along with other vaccine makers have been under pressure to increase supply for poorer countries. South Africa and other countries with tight supplies have proposed temporarily waiving patent protections so they can make the shots. Vaccine makers have opposed the measure, saying a technology transfer is a long and complex process and there is limited capacity.</p>\n<p>“We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need,” said Pfizer Chief Executive Albert Bourla.</p>\n<p>Latin America is slowly overcoming vaccine-supply problems, and&nbsp;vaccinations have risen sharply.</p>\n<p>Supply concerns could be renewed, though, should more countries prepare to administer booster shots to maintain protection against the virus. The U.S. last week recommended additional shots for adults starting next month for people vaccinated from messenger RNA vaccines such as Pfizer’s.</p>\n<p>Latin America, home to about 8% of the world’s population, accounts for roughly a&nbsp;third of global deaths&nbsp;from the pandemic, according to Johns Hopkins University.</p>\n<p>The Pfizer-BioNTech vaccine involves a new gene-based technology called mRNA. Health authorities have confronted limited supplies as companies increase manufacturing. Some of the steps have been&nbsp;tough to scale up quickly, in part because they haven’t been performed before, according to manufacturing experts and the companies.</p>\n<p>Eurofarma, based in São Paulo, will receive drug products from the U.S. and then perform a standard manufacturing step known as fill-finish, in which vials are filled with vaccines, capped and readied for shipment.</p>\n<p>“At such a difficult time as this one, being able to share this news fills us with pride and hope,”&nbsp;said Eurofarma President Maurizio Billi.</p>\n<p>Pfizer and BioNTech say they have shipped more than 1.3 billion doses to more than 120 countries and territories around the world. The companies say they can produce about three billion doses this year and four billion next year.</p>\n<p>Other vaccine makers, including&nbsp;Moderna&nbsp;Inc.&nbsp;and&nbsp;AstraZeneca&nbsp;PLC, have alsoturned to outside manufacturersto increase production.</p>\n<p>Pfizer and BioNTech have&nbsp;struck manufacturing partnerships&nbsp;with rival drugmakers such asNovartisAGas well as other companies such as&nbsp;Thermo Fisher Scientific&nbsp;Inc.Pfizer and BioNTech said the manufacturing network for the vaccine now spans four continents and more than 20 plants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech Expand Covid-19 Vaccine Manufacturing Into Latin America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 19:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region\nEurofarma will perform a manufacturing step known as fill-finish for the Pfizer-...</p>\n\n<a href=\"https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.wsj.com/articles/pfizer-biontech-expand-covid-19-vaccine-manufacturing-into-latin-america-11629974701?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171909968","content_text":"Deal would allow Brazil’s Eurofarma to produce at least 100 million doses annually for distribution in the region\nEurofarma will perform a manufacturing step known as fill-finish for the Pfizer-BioNTech vaccine.\nPfizerInc. and BioNTech SE said they are partnering with a Brazilian pharmaceutical company to help manufacture their Covid-19 vaccine in Latin America, which could help meet growing demand for the shot in the region.\nEurofarma will produce at least 100 million doses annually for distribution in the region, Pfizer and BioNTech said Thursday.\nThe doses will be in addition to those reaching Latin America through distribution channels such as Covax, the global initiative intended to get vaccines to low-income countries, and donations by the U.S., the companies said.\nPfizer and BioNTech said manufacturing will begin next year, after the companies have completed a lengthy process known as technology transfer, in which they provide Eurofarma with top-secret information about the vaccine, manufacturing know-how and other key details.\nThe Eurofarma deal is the first in Latin America for the shot from Pfizer and BioNTech, which along with other vaccine makers have been under pressure to increase supply for poorer countries. South Africa and other countries with tight supplies have proposed temporarily waiving patent protections so they can make the shots. Vaccine makers have opposed the measure, saying a technology transfer is a long and complex process and there is limited capacity.\n“We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need,” said Pfizer Chief Executive Albert Bourla.\nLatin America is slowly overcoming vaccine-supply problems, and vaccinations have risen sharply.\nSupply concerns could be renewed, though, should more countries prepare to administer booster shots to maintain protection against the virus. The U.S. last week recommended additional shots for adults starting next month for people vaccinated from messenger RNA vaccines such as Pfizer’s.\nLatin America, home to about 8% of the world’s population, accounts for roughly a third of global deaths from the pandemic, according to Johns Hopkins University.\nThe Pfizer-BioNTech vaccine involves a new gene-based technology called mRNA. Health authorities have confronted limited supplies as companies increase manufacturing. Some of the steps have been tough to scale up quickly, in part because they haven’t been performed before, according to manufacturing experts and the companies.\nEurofarma, based in São Paulo, will receive drug products from the U.S. and then perform a standard manufacturing step known as fill-finish, in which vials are filled with vaccines, capped and readied for shipment.\n“At such a difficult time as this one, being able to share this news fills us with pride and hope,” said Eurofarma President Maurizio Billi.\nPfizer and BioNTech say they have shipped more than 1.3 billion doses to more than 120 countries and territories around the world. The companies say they can produce about three billion doses this year and four billion next year.\nOther vaccine makers, including Moderna Inc. and AstraZeneca PLC, have alsoturned to outside manufacturersto increase production.\nPfizer and BioNTech have struck manufacturing partnerships with rival drugmakers such asNovartisAGas well as other companies such as Thermo Fisher Scientific Inc.Pfizer and BioNTech said the manufacturing network for the vaccine now spans four continents and more than 20 plants.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891182524,"gmtCreate":1628349184668,"gmtModify":1633751515667,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/891182524","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899971972,"gmtCreate":1628155634196,"gmtModify":1633753094090,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899971972","repostId":"1129515398","repostType":4,"repost":{"id":"1129515398","kind":"news","pubTimestamp":1628151873,"share":"https://ttm.financial/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806132514,"gmtCreate":1627639750838,"gmtModify":1633757542718,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806132514","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://ttm.financial/m/news/1135561812?lang=&edition=full","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p>\n<ul>\n <li>AMD's margin gains are driven by growing strength in end markets.</li>\n <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>\n <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>\n <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p>\n<p>AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p>\n<p><b>Why AMD is worth $120</b></p>\n<p>Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p>\n<p>I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p>\n<p>Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>Turning to cash flow.</p>\n<p>AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p>\n<p>AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p>\n<p><b>Challenges to my price target</b></p>\n<p>The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p>\n<p>Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p>\n<p><b>Final thoughts</b></p>\n<p>AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could...</p>\n\n<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175572382,"gmtCreate":1627044519946,"gmtModify":1633768518542,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175572382","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":507,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158139403,"gmtCreate":1625134833002,"gmtModify":1633944424001,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158139403","repostId":"1178516480","repostType":4,"repost":{"id":"1178516480","kind":"news","pubTimestamp":1625094708,"share":"https://ttm.financial/m/news/1178516480?lang=&edition=full","pubTime":"2021-07-01 07:11","market":"us","language":"en","title":"S&P 500 notches fifth straight record closing high, fifth straight quarterly gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1178516480","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as inves","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p>\n<p>In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p>\n<p>All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p>\n<p>“It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p>\n<p>For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p>\n<p>This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p>\n<p>“Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p>\n<p>“(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p>\n<p>“Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p>\n<p>(Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p>\n<p><img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p>\n<p>The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p>\n<p>The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p>\n<p>Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p>\n<p>Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p>\n<p>Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p>\n<p>Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p>\n<p>Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 notches fifth straight record closing high, fifth straight quarterly gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 notches fifth straight record closing high, fifth straight quarterly gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-01 07:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking ...</p>\n\n<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178516480","content_text":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.\nIn the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.\nAll three indexes posted their fifth consecutive quarterly gains, with the S&P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&P 500 registered its second-best first-half performance since 1998, rising 14.5%.\n“It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”\nFor the month, the bellwether S&P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.\nThis month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.\n“Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”\n“(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.\n“Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”\n(Graphic: Growths stocks outperform value in June, narrow YTD gap, )\n“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”\nThe private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.\nThe Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.\nAmong the 11 major sectors in the S&P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.\nBoeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.\nWalmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.\nMicron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.\nThe S&P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.\nVolume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151033711,"gmtCreate":1625056532133,"gmtModify":1633945394672,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy All","listText":"Buy All","text":"Buy All","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/151033711","repostId":"1153621389","repostType":4,"repost":{"id":"1153621389","kind":"news","pubTimestamp":1625012260,"share":"https://ttm.financial/m/news/1153621389?lang=&edition=full","pubTime":"2021-06-30 08:17","market":"us","language":"en","title":"Forget crypto — this is the ‘next big thing’ investors should focus on, according to UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=1153621389","media":"CNBC","summary":"UBS isn’t a fan of bitcoin and other cryptocurrencies, describing them as a “speculative market” and","content":"<div>\n<p>UBS isn’t a fan of bitcoin and other cryptocurrencies, describing them as a “speculative market” and urging investors to consider an alternative instead.\nIn a note released Monday, the Swiss ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/29/ubs-forget-crypto-this-is-the-next-big-thing-for-investors.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forget crypto — this is the ‘next big thing’ investors should focus on, according to UBS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForget crypto — this is the ‘next big thing’ investors should focus on, according to UBS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 08:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/29/ubs-forget-crypto-this-is-the-next-big-thing-for-investors.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>UBS isn’t a fan of bitcoin and other cryptocurrencies, describing them as a “speculative market” and urging investors to consider an alternative instead.\nIn a note released Monday, the Swiss ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/29/ubs-forget-crypto-this-is-the-next-big-thing-for-investors.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"V":"Visa","PYPL":"PayPal","MA":"万事达"},"source_url":"https://www.cnbc.com/2021/06/29/ubs-forget-crypto-this-is-the-next-big-thing-for-investors.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1153621389","content_text":"UBS isn’t a fan of bitcoin and other cryptocurrencies, describing them as a “speculative market” and urging investors to consider an alternative instead.\nIn a note released Monday, the Swiss investment bank said that regulation poses a significant risk to digital assets.\nEarlier this month, China spooked bitcoin investors with a crackdown on cryptocurrency mining and trading.\nMore recently, the U.K.’s markets watchdog ordered Binance, a top crypto exchange, tocease regulated activitiesin the country.\n“We’ve long warned that shifting investor sentiment or regulatory crackdowns could pop bubble-like crypto markets,” UBS’ global wealth management team said in the note.\n“We think investors should avoid crypto speculation, and consider risk-adjusted returns before buying alternative assets.”\nInvestors looking to make investments in digital finance should look to the fast-growing financial technology sector, UBS said, calling fintech “one of the emerging sectors we think might yield ‘The Next Big Thing.’”\n“The prospect of large gains may tempt investors, but we think speculation in cryptos is a gamble, not an investment,” the bank said.\n“Investors looking for exposure to digital payment assets can consider fintech instead, which we expect to benefit from structural growth.”\nWhile the bank didn’t name any stocks, fintech companies like Square and PayPal have experienced sizable gains over the past year, climbing 140% and 74% respectively. Payment networks Visa and Mastercard, meanwhile, are up 23% and 26% respectively. That’s thanks in no small part to a rise in digital payment volumes during the coronavirus pandemic.\nWhat’s weighing on bitcoin?\nBitcoin is currently down around 45% from its record high of nearly $65,000 in April. It was last trading at around $35,835, up 4% in the last 24 hours, as of Tuesday.\nThe world’s largest digital coin had benefited from an influx of institutional investorsditching gold in favor of bitcoinas an inflation hedge. However, that trendappears to have reversedmore recently.\nUBS said a number of other factors are weighing on bitcoin. It alluded to news that Boston Federal Reserve President Eric Rosengren called tether — a controversial stablecoin tied to the U.S. dollar — a financial stability challenge.\nThe bank also highlighted the case of Africrypt, a South African crypto exchange whose founders havereportedly disappeared, taking $3.6 billion in client funds with them.\n“While the pandemic may ensure financial repression continues, we think crypto speculation poses its own risks to your wealth,” UBS said.","news_type":1,"symbols_score_info":{"MA":0.9,"PYPL":0.9,"SQ":0.9,"V":0.9}},"isVote":1,"tweetType":1,"viewCount":495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":371162287,"gmtCreate":1618921575449,"gmtModify":1634289903336,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Booster","listText":"Booster","text":"Booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/371162287","repostId":"1185485095","repostType":4,"repost":{"id":"1185485095","kind":"news","pubTimestamp":1618809881,"share":"https://ttm.financial/m/news/1185485095?lang=&edition=full","pubTime":"2021-04-19 13:24","market":"us","language":"en","title":"What to expect at Apple's 'Spring loaded' event","url":"https://stock-news.laohu8.com/highlight/detail?id=1185485095","media":"CNN Business","summary":"If the \"Spring loaded\" tagline of Apple's upcoming press event is any indication, the company is about to drop a ton of new products.Apple  is hosting its first event of 2021 on Tuesday and it'll likely focus on new iPads, along with a product that's been years in the making.The invitations for the virtual press conference sent to reporters last week included an image of colorful spirals that form the Apple logo — a picture potentially made to look as if it had been produced by an Apple Pencil, ","content":"<p>(CNN Business)If the \"Spring loaded\" tagline of Apple's upcoming press event is any indication, the company is about to drop a ton of new products.</p><p>Apple (AAPL) is hosting its first event of 2021 on Tuesday and it'll likely focus on new iPads, along with a product that's been years in the making.</p><p>The invitations for the virtual press conference sent to reporters last week included an image of colorful spirals that form the Apple logo — a picture potentially made to look as if it had been produced by an Apple Pencil, a clue hinting at updates to its iPad line.</p><p>The company's invitations are often filled with red herrings, but Apple senior marketing executive Greg Joswiak added to the fodder when he tweeted a video featuring an animation of the spirals bouncing around Apple's campus. It sparked speculation that augmented reality could also be part of the company's presentation.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ae2d578c2ecc4d60db5042317b1efc\" tg-width=\"780\" tg-height=\"438\"><span>The image included in invitations to the press hints at new iPads and augmented reality</span></p><p><b>iPad Pro</b></p><p>Two things are usually a given each springtime: blossoming flowers and the arrival of next-generation iPads. The company isexpectedto show off an updated iPad Pro with a faster processor, 5G support, a Thunderbolt port so it can connect to more external monitors and a Mini LED display.</p><p>The display is expected to increase brightness, offer a higher contrast ratio, improve power efficiencies for a longer battery life but be slightly thicker than current versions. It's possible Apple will also show off a redesigned iPad mini with smaller bezels and a larger display. But it's unclear if any of these updates will be enough to convince users to upgrade.</p><p>Eleftheria Kouri, an analyst at tech market advisory firm ABI Research, said tablet shipments significantly increased in 2020, thanks in part to remote learning and working. But that uptick won't last forever. \"Tablet vendors, including Apple, need to introduce a really game changing technological feature in order to boost sales and encourage consumers to replace their old devices: 5G connectivity is one of these key features,\" she said.</p><p><b>AirTags</b></p><p>Perhaps the buzziest product in the rumor mill is the potential debut of AirTags, a Tile-like Bluetooth locator that attaches to and helps you find items such as keys, wallets, laptops or even your car. AirTags have been reportedly in the works as far back as 2019 when pictures hidden within iOS 13 suggested small, flat, circular discs with built-in chips could allow someone to locate items when connected to Apple's Find My app.</p><p>This is where AR could come into play. In iOS 13, a string of code stated: \"Walk around several feet and move your iPhone up and down until a balloon comes into view,\" indicating where an item may be hiding, according to MacRumors.</p><p><b>Apple TV, privacy features and more</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4526e5862263783d6373c9bd51276f77\" tg-width=\"780\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><span>Tim Cook, CEO of Apple unveils a new iPad Pro during a launch event at the Brooklyn Academy of Music on October 30, 2018 in New York City.</span></p><p>Not only is the Apple TV due for a new processor and better refresh support for gaming, a redesigned remote could work as a physical locator for AirTags, according to tech blog 9to5Mac.</p><p>And then there's AirPods 3. The next-generation of Apple's wireless earbuds are believed to have a design more in line with its higher-end AirPods Pro, along with spatial audio support and touch controls. AirPods have cultivated a cult-like following over the years and emerged as a fashion and status symbol, but it's possible Apple could wait until later this year to show off a new model.</p><p>Apple's MacBook Pro and MacBook Air are also due for refreshes, but it's unclear if they'll get one as early as next week. Apple recently discontinued its iMac Pro line, once the most-powerful computer the company offered, and its original HomePod to focus more on the HomePod mini.</p><p>The company could also walk users through an expected iOS 14.5 software update focused on privacy. Its upcoming App Tracking Transparency feature will require app developers to explicitly divulge how they're collecting user data, what it'll be used for, and require user consent before they download or update apps from the App Store.</p><p>Still, all eyes will be on the lookout for new gadgets on Tuesday. \"Despite the disruptions in the production line, crisis in the semiconductor industry and economic uncertainty that was caused by pandemic, demand for consumer products generally remained resilient,\" said Kouri.</p><p>ABI Research expects demand for certain products, such as true wireless earbuds and 5G devices, will see explosive growth the coming years, but tech companies like Apple will first have to provide enough incentive for consumers to spend their dollars.</p><p>Apple's event kicks off at 1:00 p.m. ET/10:00 a.m. PT on its website, YouTube and Apple TV.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What to expect at Apple's 'Spring loaded' event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat to expect at Apple's 'Spring loaded' event\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/04/18/tech/apple-ipad-event-2021/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(CNN Business)If the \"Spring loaded\" tagline of Apple's upcoming press event is any indication, the company is about to drop a ton of new products.Apple (AAPL) is hosting its first event of 2021 on ...</p>\n\n<a href=\"https://edition.cnn.com/2021/04/18/tech/apple-ipad-event-2021/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://edition.cnn.com/2021/04/18/tech/apple-ipad-event-2021/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185485095","content_text":"(CNN Business)If the \"Spring loaded\" tagline of Apple's upcoming press event is any indication, the company is about to drop a ton of new products.Apple (AAPL) is hosting its first event of 2021 on Tuesday and it'll likely focus on new iPads, along with a product that's been years in the making.The invitations for the virtual press conference sent to reporters last week included an image of colorful spirals that form the Apple logo — a picture potentially made to look as if it had been produced by an Apple Pencil, a clue hinting at updates to its iPad line.The company's invitations are often filled with red herrings, but Apple senior marketing executive Greg Joswiak added to the fodder when he tweeted a video featuring an animation of the spirals bouncing around Apple's campus. It sparked speculation that augmented reality could also be part of the company's presentation.The image included in invitations to the press hints at new iPads and augmented realityiPad ProTwo things are usually a given each springtime: blossoming flowers and the arrival of next-generation iPads. The company isexpectedto show off an updated iPad Pro with a faster processor, 5G support, a Thunderbolt port so it can connect to more external monitors and a Mini LED display.The display is expected to increase brightness, offer a higher contrast ratio, improve power efficiencies for a longer battery life but be slightly thicker than current versions. It's possible Apple will also show off a redesigned iPad mini with smaller bezels and a larger display. But it's unclear if any of these updates will be enough to convince users to upgrade.Eleftheria Kouri, an analyst at tech market advisory firm ABI Research, said tablet shipments significantly increased in 2020, thanks in part to remote learning and working. But that uptick won't last forever. \"Tablet vendors, including Apple, need to introduce a really game changing technological feature in order to boost sales and encourage consumers to replace their old devices: 5G connectivity is one of these key features,\" she said.AirTagsPerhaps the buzziest product in the rumor mill is the potential debut of AirTags, a Tile-like Bluetooth locator that attaches to and helps you find items such as keys, wallets, laptops or even your car. AirTags have been reportedly in the works as far back as 2019 when pictures hidden within iOS 13 suggested small, flat, circular discs with built-in chips could allow someone to locate items when connected to Apple's Find My app.This is where AR could come into play. In iOS 13, a string of code stated: \"Walk around several feet and move your iPhone up and down until a balloon comes into view,\" indicating where an item may be hiding, according to MacRumors.Apple TV, privacy features and moreTim Cook, CEO of Apple unveils a new iPad Pro during a launch event at the Brooklyn Academy of Music on October 30, 2018 in New York City.Not only is the Apple TV due for a new processor and better refresh support for gaming, a redesigned remote could work as a physical locator for AirTags, according to tech blog 9to5Mac.And then there's AirPods 3. The next-generation of Apple's wireless earbuds are believed to have a design more in line with its higher-end AirPods Pro, along with spatial audio support and touch controls. AirPods have cultivated a cult-like following over the years and emerged as a fashion and status symbol, but it's possible Apple could wait until later this year to show off a new model.Apple's MacBook Pro and MacBook Air are also due for refreshes, but it's unclear if they'll get one as early as next week. Apple recently discontinued its iMac Pro line, once the most-powerful computer the company offered, and its original HomePod to focus more on the HomePod mini.The company could also walk users through an expected iOS 14.5 software update focused on privacy. Its upcoming App Tracking Transparency feature will require app developers to explicitly divulge how they're collecting user data, what it'll be used for, and require user consent before they download or update apps from the App Store.Still, all eyes will be on the lookout for new gadgets on Tuesday. \"Despite the disruptions in the production line, crisis in the semiconductor industry and economic uncertainty that was caused by pandemic, demand for consumer products generally remained resilient,\" said Kouri.ABI Research expects demand for certain products, such as true wireless earbuds and 5G devices, will see explosive growth the coming years, but tech companies like Apple will first have to provide enough incentive for consumers to spend their dollars.Apple's event kicks off at 1:00 p.m. ET/10:00 a.m. PT on its website, YouTube and Apple TV.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175572382,"gmtCreate":1627044519946,"gmtModify":1633768518542,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175572382","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":507,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105445400,"gmtCreate":1620323554900,"gmtModify":1634206084849,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Up or down?&nbsp;","listText":"Up or down?&nbsp;","text":"Up or down?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/105445400","repostId":"2133387578","repostType":4,"repost":{"id":"2133387578","kind":"highlight","pubTimestamp":1620296700,"share":"https://ttm.financial/m/news/2133387578?lang=&edition=full","pubTime":"2021-05-06 18:25","market":"us","language":"en","title":"Think Stocks Will Crash in May? Do These 4 Things Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2133387578","media":"Motley Fool","summary":"Stock market downturns can be daunting. Here's what you need to do to prepare.","content":"<p>When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely in the near term, investors should at the very least begin bracing for a correction, where stock values drop 10% or more.</p>\n<p>Of course, the idea of a stock market crash can be very scary, especially if you're a newer investor and you haven't experienced <a href=\"https://laohu8.com/S/AONE\">one</a> before. But rather than allow yourself to get spooked, you're better off taking action. Here are a few crucial moves to make if you're worried that May is when the stock market will finally take a major turn for the worse.</p>\n<h2>1. Pad your emergency savings</h2>\n<p>What does the amount of money you have in the bank have to do with your stock portfolio? A lot, actually. If you secure your emergency fund so you have ample cash to cover unplanned expenses, you won't have to tap your investments out of desperation. That could, in turn, prevent you from needing to liquidate stocks at a time when their value has dropped substantially.</p>\n<h2>2. Diversify</h2>\n<p>A diverse portfolio could help you ride out a stock market crash, so if you're heavily invested in <a href=\"https://laohu8.com/S/AONE.U\">one</a> or two market segments right now, take the opportunity to branch out -- before things take a turn for the worse. Diversifying could simply mean buying stocks in sectors you're not currently invested in. Or you could load up on some index funds or exchange-traded funds (ETFs) that give you access to the broader market. For example, if you invest in an <b>S&amp;P 500</b> index fund or ETF, you'll effectively be putting money into the 500 largest publicly traded companies on the market. It doesn't get much more diverse than that.</p>\n<h2>3. Add dividend stocks to your portfolio</h2>\n<p>Companies that pay dividends tend to do so even when stock values are down. And that's a good way to hedge your bets. If your portfolio takes a hit, you can offset those losses with incoming dividend payments, and that's money you'll have the option to cash out and use as needed or reinvest.</p>\n<h2>4. Stockpile some cash</h2>\n<p>Market crashes tend to spell opportunity, and so it's important to have cash at the ready for when stocks go on sale. While your first priority should be to shore up your emergency fund, if you're also able to divert some extra cash to your brokerage account, you'll put yourself in a great position to pounce while stocks are temporarily discounted.</p>\n<p>Even if you're a seasoned investor who follows the market closely, you probably won't be able to predict exactly when the stock market will crash next. While a May crash is certainly possible, it's also certainly not a given. But rather than spin your wheels trying to determine when that crash is coming, you should instead focus your energy on checking off the boxes above. That way, you'll really be ready for whatever is ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Think Stocks Will Crash in May? Do These 4 Things Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThink Stocks Will Crash in May? Do These 4 Things Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 18:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2133387578","content_text":"When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely in the near term, investors should at the very least begin bracing for a correction, where stock values drop 10% or more.\nOf course, the idea of a stock market crash can be very scary, especially if you're a newer investor and you haven't experienced one before. But rather than allow yourself to get spooked, you're better off taking action. Here are a few crucial moves to make if you're worried that May is when the stock market will finally take a major turn for the worse.\n1. Pad your emergency savings\nWhat does the amount of money you have in the bank have to do with your stock portfolio? A lot, actually. If you secure your emergency fund so you have ample cash to cover unplanned expenses, you won't have to tap your investments out of desperation. That could, in turn, prevent you from needing to liquidate stocks at a time when their value has dropped substantially.\n2. Diversify\nA diverse portfolio could help you ride out a stock market crash, so if you're heavily invested in one or two market segments right now, take the opportunity to branch out -- before things take a turn for the worse. Diversifying could simply mean buying stocks in sectors you're not currently invested in. Or you could load up on some index funds or exchange-traded funds (ETFs) that give you access to the broader market. For example, if you invest in an S&P 500 index fund or ETF, you'll effectively be putting money into the 500 largest publicly traded companies on the market. It doesn't get much more diverse than that.\n3. Add dividend stocks to your portfolio\nCompanies that pay dividends tend to do so even when stock values are down. And that's a good way to hedge your bets. If your portfolio takes a hit, you can offset those losses with incoming dividend payments, and that's money you'll have the option to cash out and use as needed or reinvest.\n4. Stockpile some cash\nMarket crashes tend to spell opportunity, and so it's important to have cash at the ready for when stocks go on sale. While your first priority should be to shore up your emergency fund, if you're also able to divert some extra cash to your brokerage account, you'll put yourself in a great position to pounce while stocks are temporarily discounted.\nEven if you're a seasoned investor who follows the market closely, you probably won't be able to predict exactly when the stock market will crash next. While a May crash is certainly possible, it's also certainly not a given. But rather than spin your wheels trying to determine when that crash is coming, you should instead focus your energy on checking off the boxes above. That way, you'll really be ready for whatever is ahead.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345099607,"gmtCreate":1618251374009,"gmtModify":1634294159460,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Up down up down.&nbsp;","listText":"Up down up down.&nbsp;","text":"Up down up down.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/345099607","repostId":"1188840982","repostType":4,"repost":{"id":"1188840982","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618237983,"share":"https://ttm.financial/m/news/1188840982?lang=&edition=full","pubTime":"2021-04-12 22:33","market":"us","language":"en","title":"GameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade","url":"https://stock-news.laohu8.com/highlight/detail?id=1188840982","media":"Tiger Newspress","summary":"(April 12) GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares","content":"<p>(April 12)&nbsp;GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.</p>\n<p><img src=\"https://static.tigerbbs.com/0e0e81ec43e109abaa82e6aae6fe9a36\" tg-width=\"663\" tg-height=\"564\">GameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.</p>\n<p>The stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.</p>\n<p>The video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.</p>\n<p>Shares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.</p>\n<p>Ascendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”</p>\n<p>The stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-12 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 12)&nbsp;GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.</p>\n<p><img src=\"https://static.tigerbbs.com/0e0e81ec43e109abaa82e6aae6fe9a36\" tg-width=\"663\" tg-height=\"564\">GameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.</p>\n<p>The stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.</p>\n<p>The video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.</p>\n<p>Shares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.</p>\n<p>Ascendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”</p>\n<p>The stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188840982","content_text":"(April 12) GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.\nGameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.\nThe stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.\nThe video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.\nShares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.\nAscendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”\nThe stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377174111,"gmtCreate":1619511122833,"gmtModify":1634212165817,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/377174111","repostId":"2130522345","repostType":4,"repost":{"id":"2130522345","kind":"highlight","pubTimestamp":1619484161,"share":"https://ttm.financial/m/news/2130522345?lang=&edition=full","pubTime":"2021-04-27 08:42","market":"us","language":"en","title":"AMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?","url":"https://stock-news.laohu8.com/highlight/detail?id=2130522345","media":"MarketWatch","summary":"AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined. AMD first launched the EPYC family of server chips in 2017. AMD. Advanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.AMD $$ is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel $$ reported results last week, the market-share leader","content":"<p>AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/615a522a230f802ea7b3c7554e6a350b\" tg-width=\"1259\" tg-height=\"709\"><span>AMD first launched the EPYC family of server chips in 2017. AMD</span></p>\n<p>Advanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.</p>\n<p>AMD <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> reported results last week, the market-share leader noted that the market was just bottoming from a \"digestion phase\" as its data-center sales dropped 20% year-over-year.</p>\n<p>Analysts questioned that characterization of a \"digestion phase,\" however, asking instead if AMD was taking share away from Intel</p>\n<p>Wall Street, on average, expects AMD to report $1.3 billion in enterprise, embedded, and semi-custom sales, the segment containing data-center and gaming-console chips, nearly triple the $348 million the company reported in the year-ago period .</p>\n<p>This all comes amid a continuing shortage of microchips to sate demand from global industries, and the companies that make the silicon wafers chip designs use, work to clear waiting lists that span several months.</p>\n<p>AMD said in its last earnings report that it expected data-center and gaming sales growth to continue well into 2021. AMD is forecast to report $1.89 billion in computing and graphics sales, a relatively modest 31% rise from a year ago.</p>\n<p>In early April, shareholders from AMD and Xilinx Inc.&nbsp;approved a $35 billion wrap-up between the two companies. In March, the company announced a&nbsp;new gaming card.</p>\n<p><b>What to expect</b></p>\n<p>Earnings: Of the 34 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 44 cents a share, up from 35 cents a share expected at the beginning of the quarter and 18 cents a share reported in the year-ago period. Estimize, a software platform that crowdsources estimates from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 48 cents a share.</p>\n<p>Revenue: Back in January, AMD predicted first-quarter sales between $3.1 billion and $3.3 billion, while analysts on average had forecast revenue of $2.68 billion at the time. Now, 31 analysts, on average, expect revenue of $3.18 billion, up from the $1.79 billion reported in the year-ago quarter. Estimize expects revenue of $3.25 billion.</p>\n<p>Stock movement: In the first quarter, AMD shares fell 14.4%. In contrast, the PHLX Semiconductor Index gained 11.8%, the S&amp;P 500 index gained 5.8%, and the tech-heavy Nasdaq Composite Index rose 2.8%.</p>\n<p><b>What analysts are saying</b></p>\n<p>Susquehanna Financial analyst Christopher Rolland, who has a positive rating and a $115 price target on AMD, said PC and graphics processing unit checks point to continued strong demand in the first quarter.</p>\n<p>\"While many believe upside is capped by capacity constraints, we believe AMD is quickly becoming [Taiwan Semiconductor Manufacturing Co.'s (2330.TW)] preferred 'CPU' partner, as Intel's IDM 2.0 strategy appears increasingly competitive to thefoundry,\" Rolland said. \"Therefore, we would not be surprised to see AMD receive more than enough wafers to track toward full-year guidance and perhaps beyond.\"</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> analyst Joseph Moore, who just reinstated estimates for AMD, said he expects strong earnings above the consensus from AMD with \"strong demand across the board, and supply constraints due to substrates and to a lesser extent wafers.\"</p>\n<p>Moore expects fab priority to keep going to high margin products like servers and \"enthusiast desktop microprocessors\" and \"lowest-margin customers that are strategic and sole sourced\" like Microsoft Corp.'s <a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a> and Sony Group Corp.'s gaming consoles.</p>\n<p>\"With competitors also dealing with supply constraints, overall pricing should be healthy,\" Moore said. The analysts expects AMD fiscal earnings of $2.04 a share in 2021, $2.59 a share in 2022, and $2.90 a share in 2023, while analysts surveyed by FactSet expect per-share earnings of $1.95, $2.51, and $3.23, respectively.</p>\n<p>B of A Securities analyst Vivek Arya, who has a $100 price target, said of the larger chip market that \"Supply constraints could limit Q1 outperformance/Q2 outlook, but extend cycle into CY22\"</p>\n<p>For AMD, \"can it obtain enough incremental supply from TSMC to beat its already robust 37% YoY sales outlook for CY21 while firmly convincing investors around INTC share gains?\"</p>\n<p>Of the 36 analysts who cover AMD, 21 have buy or overweight ratings, 12 have hold ratings and three have sell ratings, with an average price target of $100.50.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/amd-earnings-are-data-center-owners-digesting-or-just-not-buying-intel-chips-11619473180?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined\nAMD first launched the EPYC family of server chips in 2017. AMD\nAdvanced ...</p>\n\n<a href=\"https://www.marketwatch.com/story/amd-earnings-are-data-center-owners-digesting-or-just-not-buying-intel-chips-11619473180?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.marketwatch.com/story/amd-earnings-are-data-center-owners-digesting-or-just-not-buying-intel-chips-11619473180?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2130522345","content_text":"AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined\nAMD first launched the EPYC family of server chips in 2017. AMD\nAdvanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.\nAMD $(AMD)$ is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel $(INTC)$ reported results last week, the market-share leader noted that the market was just bottoming from a \"digestion phase\" as its data-center sales dropped 20% year-over-year.\nAnalysts questioned that characterization of a \"digestion phase,\" however, asking instead if AMD was taking share away from Intel\nWall Street, on average, expects AMD to report $1.3 billion in enterprise, embedded, and semi-custom sales, the segment containing data-center and gaming-console chips, nearly triple the $348 million the company reported in the year-ago period .\nThis all comes amid a continuing shortage of microchips to sate demand from global industries, and the companies that make the silicon wafers chip designs use, work to clear waiting lists that span several months.\nAMD said in its last earnings report that it expected data-center and gaming sales growth to continue well into 2021. AMD is forecast to report $1.89 billion in computing and graphics sales, a relatively modest 31% rise from a year ago.\nIn early April, shareholders from AMD and Xilinx Inc. approved a $35 billion wrap-up between the two companies. In March, the company announced a new gaming card.\nWhat to expect\nEarnings: Of the 34 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 44 cents a share, up from 35 cents a share expected at the beginning of the quarter and 18 cents a share reported in the year-ago period. Estimize, a software platform that crowdsources estimates from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 48 cents a share.\nRevenue: Back in January, AMD predicted first-quarter sales between $3.1 billion and $3.3 billion, while analysts on average had forecast revenue of $2.68 billion at the time. Now, 31 analysts, on average, expect revenue of $3.18 billion, up from the $1.79 billion reported in the year-ago quarter. Estimize expects revenue of $3.25 billion.\nStock movement: In the first quarter, AMD shares fell 14.4%. In contrast, the PHLX Semiconductor Index gained 11.8%, the S&P 500 index gained 5.8%, and the tech-heavy Nasdaq Composite Index rose 2.8%.\nWhat analysts are saying\nSusquehanna Financial analyst Christopher Rolland, who has a positive rating and a $115 price target on AMD, said PC and graphics processing unit checks point to continued strong demand in the first quarter.\n\"While many believe upside is capped by capacity constraints, we believe AMD is quickly becoming [Taiwan Semiconductor Manufacturing Co.'s (2330.TW)] preferred 'CPU' partner, as Intel's IDM 2.0 strategy appears increasingly competitive to thefoundry,\" Rolland said. \"Therefore, we would not be surprised to see AMD receive more than enough wafers to track toward full-year guidance and perhaps beyond.\"\nMorgan Stanley analyst Joseph Moore, who just reinstated estimates for AMD, said he expects strong earnings above the consensus from AMD with \"strong demand across the board, and supply constraints due to substrates and to a lesser extent wafers.\"\nMoore expects fab priority to keep going to high margin products like servers and \"enthusiast desktop microprocessors\" and \"lowest-margin customers that are strategic and sole sourced\" like Microsoft Corp.'s $(MSFT)$ and Sony Group Corp.'s gaming consoles.\n\"With competitors also dealing with supply constraints, overall pricing should be healthy,\" Moore said. The analysts expects AMD fiscal earnings of $2.04 a share in 2021, $2.59 a share in 2022, and $2.90 a share in 2023, while analysts surveyed by FactSet expect per-share earnings of $1.95, $2.51, and $3.23, respectively.\nB of A Securities analyst Vivek Arya, who has a $100 price target, said of the larger chip market that \"Supply constraints could limit Q1 outperformance/Q2 outlook, but extend cycle into CY22\"\nFor AMD, \"can it obtain enough incremental supply from TSMC to beat its already robust 37% YoY sales outlook for CY21 while firmly convincing investors around INTC share gains?\"\nOf the 36 analysts who cover AMD, 21 have buy or overweight ratings, 12 have hold ratings and three have sell ratings, with an average price target of $100.50.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879637577,"gmtCreate":1636715008912,"gmtModify":1636715009013,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Liked","listText":"Liked","text":"Liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879637577","repostId":"1149394295","repostType":4,"repost":{"id":"1149394295","kind":"news","pubTimestamp":1636714672,"share":"https://ttm.financial/m/news/1149394295?lang=&edition=full","pubTime":"2021-11-12 18:57","market":"us","language":"en","title":"Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch","url":"https://stock-news.laohu8.com/highlight/detail?id=1149394295","media":"Reuters","summary":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar","content":"<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p>\n<p>Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p>\n<p>The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p>\n<p>It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p>\n<p>Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p>\n<p>On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p>\n<p>He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p>\n<p>Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p>\n<p>According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p>\n<p>\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatura &Co posts $50 mln quarterly profit; plans share buyback, listing switch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTCO":"Natura & Co Holding SA"},"source_url":"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149394295","content_text":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.\nNatura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.\nThe company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.\nIt reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.\nNatura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.\nOn the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.\nHe praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.\nMarques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.\nAccording to Marques, Natura has had a hard time raising prices as key markets deal with these issues.\n\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.","news_type":1,"symbols_score_info":{"NTCO":0.9}},"isVote":1,"tweetType":1,"viewCount":2398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":806132514,"gmtCreate":1627639750838,"gmtModify":1633757542718,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806132514","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://ttm.financial/m/news/1135561812?lang=&edition=full","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p>\n<ul>\n <li>AMD's margin gains are driven by growing strength in end markets.</li>\n <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>\n <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>\n <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p>\n<p>AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p>\n<p><b>Why AMD is worth $120</b></p>\n<p>Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p>\n<p>I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p>\n<p>Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>Turning to cash flow.</p>\n<p>AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p>\n<p>AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p>\n<p><b>Challenges to my price target</b></p>\n<p>The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p>\n<p>Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p>\n<p><b>Final thoughts</b></p>\n<p>AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could...</p>\n\n<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183586815,"gmtCreate":1623335990937,"gmtModify":1634034418706,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/183586815","repostId":"1193863762","repostType":4,"repost":{"id":"1193863762","kind":"news","pubTimestamp":1623334800,"share":"https://ttm.financial/m/news/1193863762?lang=&edition=full","pubTime":"2021-06-10 22:20","market":"us","language":"en","title":"Global Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1193863762","media":"seekingalpha","summary":"(June 10) Semiconductor stocks rose in morning trading.\nRelated: Semiconductor Watchlist: Jim Cramer","content":"<p>(June 10)&nbsp;Semiconductor&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;morning&nbsp;trading.</p>\n<p><a href=\"https://laohu8.com/NW/1163875762\" target=\"_blank\"><b>Related:&nbsp;Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom</b></a><b></b></p>\n<p><img src=\"https://static.tigerbbs.com/eb703ee8165d2dc48c5550db47dfebc7\" tg-width=\"303\" tg-height=\"363\" referrerpolicy=\"no-referrer\"></p>\n<p>According to World Semiconductor Trade Statistics estimates, the global semiconductor market will rise from 6.8% in 2020 to 19.7% thisyear to ~$527B.</p>\n<p>The most significant growth contributors are Memory with 31.7%, followed by Sensors with 22.4% and, Analog with 21.7%. All other major product categories are also expected to show double-digit growth rates, except Optoelectronics with 9.8% and MOS Micro with 8.1%.</p>\n<p>In 2021, Asia Pacific (incl. China) is forecasted to show the most robust growth rate with 23.5%, followed by Europe with 21.1%, Japan 12.7%, and the Americas with 11.1%.</p>\n<p>For 2022, the global semiconductor market is projected to grow by 8.8% to $573B, driven by double-digit growth of the Memory category. All regions are expected again to show favorable growth rates.</p>\n<p>Related stocks YTD returns: NXP Semiconductor(NASDAQ:NXPI)&nbsp;+24.7%, On Semiconducter(NASDAQ:ON)&nbsp;+14.85%, Intel(NASDAQ:INTC)&nbsp;+14.4%,&nbsp; and, TSMC(NYSE:TSM)&nbsp;+6.3%.</p>\n<p>ETFs:SMH,SOXL,SOXX,XSD,USD,SOXS,PSI,FTXL,SSG.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3704878-global-semiconductor-annual-sales-projected-to-increase-about-20-percentage-in-2021-and-9-percentage-in-2022><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 10) Semiconductor stocks rose in morning trading.\nRelated: Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom\n\nAccording to World Semiconductor Trade Statistics estimates, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3704878-global-semiconductor-annual-sales-projected-to-increase-about-20-percentage-in-2021-and-9-percentage-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔","ON":"安森美半导体","TSM":"台积电","NXPI":"恩智浦"},"source_url":"https://seekingalpha.com/news/3704878-global-semiconductor-annual-sales-projected-to-increase-about-20-percentage-in-2021-and-9-percentage-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193863762","content_text":"(June 10) Semiconductor stocks rose in morning trading.\nRelated: Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom\n\nAccording to World Semiconductor Trade Statistics estimates, the global semiconductor market will rise from 6.8% in 2020 to 19.7% thisyear to ~$527B.\nThe most significant growth contributors are Memory with 31.7%, followed by Sensors with 22.4% and, Analog with 21.7%. All other major product categories are also expected to show double-digit growth rates, except Optoelectronics with 9.8% and MOS Micro with 8.1%.\nIn 2021, Asia Pacific (incl. China) is forecasted to show the most robust growth rate with 23.5%, followed by Europe with 21.1%, Japan 12.7%, and the Americas with 11.1%.\nFor 2022, the global semiconductor market is projected to grow by 8.8% to $573B, driven by double-digit growth of the Memory category. All regions are expected again to show favorable growth rates.\nRelated stocks YTD returns: NXP Semiconductor(NASDAQ:NXPI) +24.7%, On Semiconducter(NASDAQ:ON) +14.85%, Intel(NASDAQ:INTC) +14.4%,  and, TSMC(NYSE:TSM) +6.3%.\nETFs:SMH,SOXL,SOXX,XSD,USD,SOXS,PSI,FTXL,SSG.","news_type":1,"symbols_score_info":{"INTC":0.9,"NXPI":0.9,"ON":0.9,"TSM":0.9}},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891182524,"gmtCreate":1628349184668,"gmtModify":1633751515667,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/891182524","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899971972,"gmtCreate":1628155634196,"gmtModify":1633753094090,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899971972","repostId":"1129515398","repostType":4,"repost":{"id":"1129515398","kind":"news","pubTimestamp":1628151873,"share":"https://ttm.financial/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":859021205,"gmtCreate":1634641639710,"gmtModify":1634641747081,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859021205","repostId":"1111431743","repostType":4,"repost":{"id":"1111431743","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634637193,"share":"https://ttm.financial/m/news/1111431743?lang=&edition=full","pubTime":"2021-10-19 17:53","market":"us","language":"en","title":"Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business","url":"https://stock-news.laohu8.com/highlight/detail?id=1111431743","media":"Benzinga","summary":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo","content":"<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p>\n<p><b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p>\n<p>The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p>\n<p><b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p>\n<p>Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p>\n<p>The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p>\n<p><b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-19 17:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p>\n<p><b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p>\n<p>The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p>\n<p><b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p>\n<p>Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p>\n<p>The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p>\n<p><b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111431743","content_text":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.\nWhat Happened: The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.\nThe design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.\nWhy It Matters: The semiconductor foray replicates similar moves from rival computing players such as Huawei Technologies and Amazon.com Inc.\nAlibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.\nThe Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.\nPrice Action: Alibaba shares closed 0.68% lower at $166.82 a share on Monday.","news_type":1,"symbols_score_info":{"09988":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":2199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862950901,"gmtCreate":1632832381619,"gmtModify":1632832381719,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862950901","repostId":"2170670597","repostType":4,"isVote":1,"tweetType":1,"viewCount":2537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":114580397,"gmtCreate":1623079650319,"gmtModify":1634037159884,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114580397","repostId":"1196162025","repostType":4,"repost":{"id":"1196162025","kind":"news","pubTimestamp":1623049574,"share":"https://ttm.financial/m/news/1196162025?lang=&edition=full","pubTime":"2021-06-07 15:06","market":"us","language":"en","title":"The second-half recovery is underway, and these are the top stocks to own, analysts say","url":"https://stock-news.laohu8.com/highlight/detail?id=1196162025","media":"cnbc","summary":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as ","content":"<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The second-half recovery is underway, and these are the top stocks to own, analysts say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe second-half recovery is underway, and these are the top stocks to own, analysts say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BKNG":"Booking Holdings","SPG":"西蒙地产","MTCH":"Match Group, Inc.","WMG":"华纳音乐"},"source_url":"https://www.cnbc.com/2021/06/06/analysts-like-top-stocks-for-the-recovery-match-booking-holdings.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1196162025","content_text":"The reopening is well underway, and this week Wall Street analysts named some of their top ideas as the second half of 2021 nears.Analysts say the time is now for investors to begin taking advantage of the economic recovery and the growing number of quality buying opportunities.CNBC Pro combed through the top Wall Street research to find stocks that should bounce back quickly as 2021 rolls on.They include:Audacy,Booking Holdings,Warner Music Group,MatchandSimon.Match GroupThe online dating app company is poised to break out as mobility improves, according to Susquehanna analyst Shyam Patil.“Lots of upside potential still left ahead,” Patil wrote in a recent note.Match, which owns Tinder and several other dating websites, reported a robust earnings report in early may where it beat on revenue.“Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q,” he said.Even as shares are down about 8.7% this year and have struggled under the weight of the pandemic, Patil said investors should stick with the stock.“We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely second-half recovery should be a strong tail wind and would recommend taking advantage of the recent dip in the shares,” he wrote.It should be no surprise then, Patil added, that Match revenue continues to accelerate, especially as consumers reenter society.“MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.,” the firm wrote.Simon Property GroupA strong recovery is finally in sight for the beleaguered real estate investment trust and owner of malls and outlet centers, Piper Sandler analyst Alexander Goldfarb wrote in a recent note.The firm raised its price target on Simon to a Street high price target of $150 per share from $130 after the company reported strong first-quarter earnings in May.“All in all, the strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next,” he said.Additionally, March sales were back to 2019 levels and that should give investors confidence that more foot traffic is just around corner, Goldfarb said.“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season,” he said.Goldfarb also predicted that consumers may see a familiar face return to Simon malls as it gets closer to December.“This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape,” Goldfarb said.Shares of Simon are up about 55% this year.AudacyInvestors should buy the dip in shares of the broadcast and website radio platform company, Wells Fargo analyst Steven Cahall said in a note to clients.The company, formerly known as Radio.com, is coming off a mixed first-quarter earnings report, but Cahall said he believes local customer spending is finally picking up and in some cases exceeding 2019 levels.“Audacy remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening,” he wrote.A return to growth in the second quarter is also possible, making the stock attractive right now, Cahall said.“There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of small- and mid-sized businesses returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21,” he said.The stock is also cheap, according to Cahall, who has Street high price target of $7 per share on Audacy.“We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view,” the firm wrote.Shares finished the week down 1.8%.Warner Music Group - Guggenheim, Buy rating“WMG delivered strong F2Q results with double-digit revenue growth at both Recorded Music and Music Publishing. Importantly, the company’s investments in international growth and digital initiatives support our positive long-term view based on unique intellectual property control, leadership position in new content sourcing and increasing exposure to secular growth businesses. Looking forward, we expect continued revenue strength in streaming/digital driven by a strong 2H release slate & expanded partnerships as well as recovery of COVID impacted businesses like live performances.Match - Susquehanna, Positive rating“Upside Potential Still Left Ahead. … We see MTCH as one of the strongest business franchises in the Internet sector, believe a likely 2H recovery should be a strong tailwind, and would recommend taking advantage of the recent dip in the shares. Tinder is continuing its momentum, and non-Tinder brands are crushing expectations, reaching a new record of 30% y/y growth in 1Q. We view the outlook as solid yet conservative and believe MTCH has an opportunity to further accelerate revenue in 2Q. … MTCH noted that momentum is continuing across the portfolio, partially driven by the vaccine rollouts, particularly in the U.S.”Simon Property - Piper Sandler, Overweight rating“As the return to normalcy accelerates, we expect the retail landscape to continue its robust rebound, especially into a mask-free 2021 holiday season. … Notably, sales in March were back up to 2019 levels, and with the change in CDC guidance we expect an increasing number of shoppers will feel comfortable shopping indoors post-vaccine. This even opens the door for a return of Santa in-person for the holidays, which further showcases the importance of the mall within the consumer landscape. … The strong 1Q21 beat and guidance increase, from a team known to be conservative, bodes well for the balance of this year into next.”Audacy - Wells Fargo, Overweight rating“While the local ad recovery has lagged national to begin the year, AUD expects a hockey stick return to growth beginning in 2Q. … We see no reason why reopening won’t happen so the recent pullback presents a nice entry point for this value stock, in our view. … There are early signs of pent-up demand in impacted verticals, such as restaurants, retail, and sporting events — and we believe the combination of SMB’s returning, local events coming back and digital revenue growth will drive a strong top line acceleration in 2H21. … AUD remains in our 2H recovery bucket as we expect the local ad market will snap back with reopening.”Booking Holdings - Wolfe, Outperform rating“BKNG reported mixed 1Q results, as total bookings beat consensus estimates by 19%, while Revenue and EBITDA were 2% and $90m below the Street, respectively. Management discussed improving trends through April, with U.S. hotel room nights above pre-COVID levels, as pent-up consumer demand is expected to drive a strong summer travel rebound. Trends across Europe remain more challenged given lagging vaccination rates but are expected to improve ahead of the summer months. Overall, near term results remain at depressed levels, but demand trends are picking up and hopes of a strong 2H recovery are intact.”","news_type":1,"symbols_score_info":{"AUD":0.9,"BKNG":0.9,"MTCH":0.9,"SPG":0.9,"WMG":0.9}},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130668264,"gmtCreate":1621539767258,"gmtModify":1634188331666,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/130668264","repostId":"2136010949","repostType":4,"repost":{"id":"2136010949","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1621525460,"share":"https://ttm.financial/m/news/2136010949?lang=&edition=full","pubTime":"2021-05-20 23:44","market":"us","language":"en","title":"Oatly spikes 25% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2136010949","media":"Tiger Newspress","summary":"Oatly shares opened at $21.36 each on Thursday, about 25% higher than the company’s IPO price.Oatly ","content":"<p>Oatly shares opened at $21.36&nbsp;each on Thursday, about 25% higher than the company’s IPO price.</p><p><img src=\"https://static.tigerbbs.com/dea20942dd681dbc49dc4d9b993e2bf2\" tg-width=\"1920\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"></p><p>Oatly is preparing for the next generation of diners who bring with them 'a new set of values and expectations'</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d1d5a4af914d52b8e97b3e053101a658\" tg-width=\"1260\" tg-height=\"841\" referrerpolicy=\"no-referrer\"><span>Oatly said in its prospectus that it's focused on health and sustainability, two areas of importance to customers.</span></p><p>After first filing for its IPO confidentially in February , plant-based food company <a href=\"https://laohu8.com/S/OTLY\">Oatly Group AB</a> go public Thursday.</p><p>On Wednesday, Oatly priced its initial public offering at $17 a share , at the high end of its expected range, offering 84.4 million American Depository Shares. Selling stockholders will offer 19.7 million of those shares.</p><p>The pricing valued the company at about $10 billion, and will raise about $1.43 billion. The company will trade on the Nasdaq under the ticker \"OTLY.\"</p><p>Oatly Group changed its name from Havre Global AB on March 1.</p><p>There are nine lead underwriters for the filing: <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>, JPMorgan, Credit Suisse, Barclays, Jeffries, BNP Paribas, BofA Securities, Piper Sandler and RBC Capital Markets.</p><p>Oatly is backed by private-equity group Blackstone Group, as well as celebrity names like Oprah Winfrey and Jay Z who invested $200 million in the company last summer. That investment valued the company at $2 billion at the time, according to The Wall Street Journal .</p><p>Based in Malmö, Sweden, Oatly has been in the oat milk business for 25 years. The company's product lineup now also includes frozen desserts and \"oatgurt,\" an alternative yogurt.</p><p>Toni Petersson has been Oatly's chief executive since 2012, and will join the board once the company is publicly-traded.</p><p>Christian Hanke, a former Nasdaq Stockholm executive, has served as Oatly's chief financial officer since March 2020.</p><p>The company is going public at a time when climate change and sustainability issues are top of mind for many consumers, particularly younger ones.</p><p>\"Generation Z and Millennials will become the dominant global generations in the coming years, bringing to the market a new set of values and expectations,\" the company said in its prospectus.</p><p>\"These combined factors are driving a clear rapid, accelerating growth and influx of new consumers to the plant-based dairy market.\"</p><p>According to the Plant Based Foods Association and Good Foods Institute, plant-based-food sales reached $7 billion in 2020.</p><p>Consumer Insights data quoted in the prospectus says the plant-based milk category will grow 20% to 25% over the next three years.</p><p>Oatly is focused on its role in helping to transform the food industry in order to be better for the environment and meet the health needs of its customers. The company points out that substituting a cup of Oatly for a cup of cow's milk reduces greenhouse gas emissions, land use and energy consumption.</p><p>Tastewise, which provides food and beverage data and intelligence, said in a December 2020 report that \"plant-based everything\" will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the top 10 U.S. trends for this year.</p><p>\"The number <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason consumers turn to plant-based food and beverage? Health,\" the report said.</p><p>\"Plant-based is no longer just an 'alternative' to meat, but rather a significantcategory in itself.\"</p><p>Oatly's key markets are Sweden, Germany and the U.K., though its products were available in 60,000 retail stores and 32,200 coffee shops around the world as of December 31, 2020. Among the places where customers can find Oatly is Starbucks <a href=\"https://laohu8.com/S/SBUX\">$(SBUX)$</a>, where demand was so high there was a shortage soon after the coffee chain introduced beverages made with the item.</p><p>COVID-19 has impacted Oatly's business as lockdowns around the world limited access to restaurants, bars and other dining establishments.</p><p>In 2020, Oatly had revenue of $421.4 million, up from $204.0 million the year before. However, the company reported a loss of $60.4 million \"reflecting our continued investment in production, brand awareness, new markets and product development,\" the prospectus said.</p><p>Oatly is classified as an \"emerging growth company,\" which means it does not have to make the same disclosures required of bigger public companies. A business remains an emerging growth company until it reaches a number of milestones, including annual revenue of more than $1.07 billion.</p><p>Oatly warns that it has reported losses over the last \"several\" years and expects operating and capital expenses to rise \"substantially.\"</p><p>\"Our expansion efforts may take longer or prove more expensive than we anticipate, particularly in light of the COVID-19 pandemic, and we may not succeed in increasing our revenue and margins sufficiently to offset the anticipated higher expenses,\" the company said in its prospectus.</p><p>\"We incur significant expenses in researching and developing our innovative products, building out our production and manufacturing facilities, obtaining and storing ingredients and other products and marketing the products we offer.\"</p><p>Here are five more things to know about Oatly ahead of its public debut:</p><p>Oatly will not pay a dividend for the \"foreseeable future.\" The company plans to use the proceeds from the offering as working capital, for incremental growth, including expansion, and other general purposes.</p><p>Coffee provided a gateway for Oatly in the U.S. Oatly arrived in the U.S. in 2017. The company says it \"focused on targeting coffee's tastemakers, professional baristas at independent coffee shops\" as a way to enter the market.\"</p><p>By December 31, 2020, Oatly was in more than 7,500 retail shops and 10,000 coffee shops in the U.S. Revenue in 2020 totaled $100 million in the U.S.</p><p>Oatly can also be found in 11,000 coffee and tea shops in China, and at more than 6,000 retail and specialty shops across the country, including thousands of Starbucks locations.</p><p>Limited oat supply could have a financial impact. Oatly depends on five suppliers for the oats it uses, purchasing this ingredient through millers in Sweden, Denmark, the U.S. and Belgium.</p><p>\"We have in the past experienced interruptions in the supply of oats from one supplier that resulted in delays in delivery to us,\" the company said, noting that its oat supply is also vulnerable to natural disasters such as drought or floods.</p><p>\"We could experience similar delays in the future from any of these suppliers.\"</p><p>The company also depends on select suppliers for enzymes, including one supplier that provides an enzyme for some of Oatly's products, including Barista Edition oat milk.</p><p>The main components of the company's products are manufactured in four primary facilities as of March 2021, which could also be a problem if something significant happens at any one facility.</p><p>The dairy market is highly competitive. Oatly identifies conventional dairy companies, including Dean Foods Inc. (DFODQ) and Lactalis as competitors, as well as the growing array of plant-based dairy alternative companies that are entering the market, including soy, almond, hemp and cashew milk brands.</p><p>All of these companies are competing for a finite number of retail stores, coffee shops, foodservice clients and consumers.</p><p>\"In order for us to not only maintain our market position, but also to continue to grow and acquire more consumers, some of which may be switching from traditional dairy to plant-based alternatives, we must continue to provide delicious, high-quality products, and consumers must believe in our vision for a food system that is better for people and the planet,\" the company said.</p><p>Oatly's marketing and COVID-19 might be a hurdle to growth. Oatly says that its history of \"provocative and unconventional marketing and advertising campaigns\" has gotten them into hot water, including a 2014 lawsuit filed by the Swedish dairy lobby in which the courts found Oatly was \"disparaging to dairy products.\"</p><p>\"The decision resulted in a ban on our further use of a number of expressions marketing our products in Sweden, under the penalty of liquidated damages of SEK 2 million per expression,\" the prospectus said.</p><p>The company cautions that future marketing could drive other legal action.</p><p>More recently, Oatly's Super Bowl ad made headlines , but mostly for provoking laughter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oatly spikes 25% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOatly spikes 25% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-20 23:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Oatly shares opened at $21.36&nbsp;each on Thursday, about 25% higher than the company’s IPO price.</p><p><img src=\"https://static.tigerbbs.com/dea20942dd681dbc49dc4d9b993e2bf2\" tg-width=\"1920\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"></p><p>Oatly is preparing for the next generation of diners who bring with them 'a new set of values and expectations'</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d1d5a4af914d52b8e97b3e053101a658\" tg-width=\"1260\" tg-height=\"841\" referrerpolicy=\"no-referrer\"><span>Oatly said in its prospectus that it's focused on health and sustainability, two areas of importance to customers.</span></p><p>After first filing for its IPO confidentially in February , plant-based food company <a href=\"https://laohu8.com/S/OTLY\">Oatly Group AB</a> go public Thursday.</p><p>On Wednesday, Oatly priced its initial public offering at $17 a share , at the high end of its expected range, offering 84.4 million American Depository Shares. Selling stockholders will offer 19.7 million of those shares.</p><p>The pricing valued the company at about $10 billion, and will raise about $1.43 billion. The company will trade on the Nasdaq under the ticker \"OTLY.\"</p><p>Oatly Group changed its name from Havre Global AB on March 1.</p><p>There are nine lead underwriters for the filing: <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>, JPMorgan, Credit Suisse, Barclays, Jeffries, BNP Paribas, BofA Securities, Piper Sandler and RBC Capital Markets.</p><p>Oatly is backed by private-equity group Blackstone Group, as well as celebrity names like Oprah Winfrey and Jay Z who invested $200 million in the company last summer. That investment valued the company at $2 billion at the time, according to The Wall Street Journal .</p><p>Based in Malmö, Sweden, Oatly has been in the oat milk business for 25 years. The company's product lineup now also includes frozen desserts and \"oatgurt,\" an alternative yogurt.</p><p>Toni Petersson has been Oatly's chief executive since 2012, and will join the board once the company is publicly-traded.</p><p>Christian Hanke, a former Nasdaq Stockholm executive, has served as Oatly's chief financial officer since March 2020.</p><p>The company is going public at a time when climate change and sustainability issues are top of mind for many consumers, particularly younger ones.</p><p>\"Generation Z and Millennials will become the dominant global generations in the coming years, bringing to the market a new set of values and expectations,\" the company said in its prospectus.</p><p>\"These combined factors are driving a clear rapid, accelerating growth and influx of new consumers to the plant-based dairy market.\"</p><p>According to the Plant Based Foods Association and Good Foods Institute, plant-based-food sales reached $7 billion in 2020.</p><p>Consumer Insights data quoted in the prospectus says the plant-based milk category will grow 20% to 25% over the next three years.</p><p>Oatly is focused on its role in helping to transform the food industry in order to be better for the environment and meet the health needs of its customers. The company points out that substituting a cup of Oatly for a cup of cow's milk reduces greenhouse gas emissions, land use and energy consumption.</p><p>Tastewise, which provides food and beverage data and intelligence, said in a December 2020 report that \"plant-based everything\" will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the top 10 U.S. trends for this year.</p><p>\"The number <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason consumers turn to plant-based food and beverage? Health,\" the report said.</p><p>\"Plant-based is no longer just an 'alternative' to meat, but rather a significantcategory in itself.\"</p><p>Oatly's key markets are Sweden, Germany and the U.K., though its products were available in 60,000 retail stores and 32,200 coffee shops around the world as of December 31, 2020. Among the places where customers can find Oatly is Starbucks <a href=\"https://laohu8.com/S/SBUX\">$(SBUX)$</a>, where demand was so high there was a shortage soon after the coffee chain introduced beverages made with the item.</p><p>COVID-19 has impacted Oatly's business as lockdowns around the world limited access to restaurants, bars and other dining establishments.</p><p>In 2020, Oatly had revenue of $421.4 million, up from $204.0 million the year before. However, the company reported a loss of $60.4 million \"reflecting our continued investment in production, brand awareness, new markets and product development,\" the prospectus said.</p><p>Oatly is classified as an \"emerging growth company,\" which means it does not have to make the same disclosures required of bigger public companies. A business remains an emerging growth company until it reaches a number of milestones, including annual revenue of more than $1.07 billion.</p><p>Oatly warns that it has reported losses over the last \"several\" years and expects operating and capital expenses to rise \"substantially.\"</p><p>\"Our expansion efforts may take longer or prove more expensive than we anticipate, particularly in light of the COVID-19 pandemic, and we may not succeed in increasing our revenue and margins sufficiently to offset the anticipated higher expenses,\" the company said in its prospectus.</p><p>\"We incur significant expenses in researching and developing our innovative products, building out our production and manufacturing facilities, obtaining and storing ingredients and other products and marketing the products we offer.\"</p><p>Here are five more things to know about Oatly ahead of its public debut:</p><p>Oatly will not pay a dividend for the \"foreseeable future.\" The company plans to use the proceeds from the offering as working capital, for incremental growth, including expansion, and other general purposes.</p><p>Coffee provided a gateway for Oatly in the U.S. Oatly arrived in the U.S. in 2017. The company says it \"focused on targeting coffee's tastemakers, professional baristas at independent coffee shops\" as a way to enter the market.\"</p><p>By December 31, 2020, Oatly was in more than 7,500 retail shops and 10,000 coffee shops in the U.S. Revenue in 2020 totaled $100 million in the U.S.</p><p>Oatly can also be found in 11,000 coffee and tea shops in China, and at more than 6,000 retail and specialty shops across the country, including thousands of Starbucks locations.</p><p>Limited oat supply could have a financial impact. Oatly depends on five suppliers for the oats it uses, purchasing this ingredient through millers in Sweden, Denmark, the U.S. and Belgium.</p><p>\"We have in the past experienced interruptions in the supply of oats from one supplier that resulted in delays in delivery to us,\" the company said, noting that its oat supply is also vulnerable to natural disasters such as drought or floods.</p><p>\"We could experience similar delays in the future from any of these suppliers.\"</p><p>The company also depends on select suppliers for enzymes, including one supplier that provides an enzyme for some of Oatly's products, including Barista Edition oat milk.</p><p>The main components of the company's products are manufactured in four primary facilities as of March 2021, which could also be a problem if something significant happens at any one facility.</p><p>The dairy market is highly competitive. Oatly identifies conventional dairy companies, including Dean Foods Inc. (DFODQ) and Lactalis as competitors, as well as the growing array of plant-based dairy alternative companies that are entering the market, including soy, almond, hemp and cashew milk brands.</p><p>All of these companies are competing for a finite number of retail stores, coffee shops, foodservice clients and consumers.</p><p>\"In order for us to not only maintain our market position, but also to continue to grow and acquire more consumers, some of which may be switching from traditional dairy to plant-based alternatives, we must continue to provide delicious, high-quality products, and consumers must believe in our vision for a food system that is better for people and the planet,\" the company said.</p><p>Oatly's marketing and COVID-19 might be a hurdle to growth. Oatly says that its history of \"provocative and unconventional marketing and advertising campaigns\" has gotten them into hot water, including a 2014 lawsuit filed by the Swedish dairy lobby in which the courts found Oatly was \"disparaging to dairy products.\"</p><p>\"The decision resulted in a ban on our further use of a number of expressions marketing our products in Sweden, under the penalty of liquidated damages of SEK 2 million per expression,\" the prospectus said.</p><p>The company cautions that future marketing could drive other legal action.</p><p>More recently, Oatly's Super Bowl ad made headlines , but mostly for provoking laughter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLY":"Oatly Group AB","SBUX":"星巴克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136010949","content_text":"Oatly shares opened at $21.36 each on Thursday, about 25% higher than the company’s IPO price.Oatly is preparing for the next generation of diners who bring with them 'a new set of values and expectations'Oatly said in its prospectus that it's focused on health and sustainability, two areas of importance to customers.After first filing for its IPO confidentially in February , plant-based food company Oatly Group AB go public Thursday.On Wednesday, Oatly priced its initial public offering at $17 a share , at the high end of its expected range, offering 84.4 million American Depository Shares. Selling stockholders will offer 19.7 million of those shares.The pricing valued the company at about $10 billion, and will raise about $1.43 billion. The company will trade on the Nasdaq under the ticker \"OTLY.\"Oatly Group changed its name from Havre Global AB on March 1.There are nine lead underwriters for the filing: Morgan Stanley, JPMorgan, Credit Suisse, Barclays, Jeffries, BNP Paribas, BofA Securities, Piper Sandler and RBC Capital Markets.Oatly is backed by private-equity group Blackstone Group, as well as celebrity names like Oprah Winfrey and Jay Z who invested $200 million in the company last summer. That investment valued the company at $2 billion at the time, according to The Wall Street Journal .Based in Malmö, Sweden, Oatly has been in the oat milk business for 25 years. The company's product lineup now also includes frozen desserts and \"oatgurt,\" an alternative yogurt.Toni Petersson has been Oatly's chief executive since 2012, and will join the board once the company is publicly-traded.Christian Hanke, a former Nasdaq Stockholm executive, has served as Oatly's chief financial officer since March 2020.The company is going public at a time when climate change and sustainability issues are top of mind for many consumers, particularly younger ones.\"Generation Z and Millennials will become the dominant global generations in the coming years, bringing to the market a new set of values and expectations,\" the company said in its prospectus.\"These combined factors are driving a clear rapid, accelerating growth and influx of new consumers to the plant-based dairy market.\"According to the Plant Based Foods Association and Good Foods Institute, plant-based-food sales reached $7 billion in 2020.Consumer Insights data quoted in the prospectus says the plant-based milk category will grow 20% to 25% over the next three years.Oatly is focused on its role in helping to transform the food industry in order to be better for the environment and meet the health needs of its customers. The company points out that substituting a cup of Oatly for a cup of cow's milk reduces greenhouse gas emissions, land use and energy consumption.Tastewise, which provides food and beverage data and intelligence, said in a December 2020 report that \"plant-based everything\" will be one of the top 10 U.S. trends for this year.\"The number one reason consumers turn to plant-based food and beverage? Health,\" the report said.\"Plant-based is no longer just an 'alternative' to meat, but rather a significantcategory in itself.\"Oatly's key markets are Sweden, Germany and the U.K., though its products were available in 60,000 retail stores and 32,200 coffee shops around the world as of December 31, 2020. Among the places where customers can find Oatly is Starbucks $(SBUX)$, where demand was so high there was a shortage soon after the coffee chain introduced beverages made with the item.COVID-19 has impacted Oatly's business as lockdowns around the world limited access to restaurants, bars and other dining establishments.In 2020, Oatly had revenue of $421.4 million, up from $204.0 million the year before. However, the company reported a loss of $60.4 million \"reflecting our continued investment in production, brand awareness, new markets and product development,\" the prospectus said.Oatly is classified as an \"emerging growth company,\" which means it does not have to make the same disclosures required of bigger public companies. A business remains an emerging growth company until it reaches a number of milestones, including annual revenue of more than $1.07 billion.Oatly warns that it has reported losses over the last \"several\" years and expects operating and capital expenses to rise \"substantially.\"\"Our expansion efforts may take longer or prove more expensive than we anticipate, particularly in light of the COVID-19 pandemic, and we may not succeed in increasing our revenue and margins sufficiently to offset the anticipated higher expenses,\" the company said in its prospectus.\"We incur significant expenses in researching and developing our innovative products, building out our production and manufacturing facilities, obtaining and storing ingredients and other products and marketing the products we offer.\"Here are five more things to know about Oatly ahead of its public debut:Oatly will not pay a dividend for the \"foreseeable future.\" The company plans to use the proceeds from the offering as working capital, for incremental growth, including expansion, and other general purposes.Coffee provided a gateway for Oatly in the U.S. Oatly arrived in the U.S. in 2017. The company says it \"focused on targeting coffee's tastemakers, professional baristas at independent coffee shops\" as a way to enter the market.\"By December 31, 2020, Oatly was in more than 7,500 retail shops and 10,000 coffee shops in the U.S. Revenue in 2020 totaled $100 million in the U.S.Oatly can also be found in 11,000 coffee and tea shops in China, and at more than 6,000 retail and specialty shops across the country, including thousands of Starbucks locations.Limited oat supply could have a financial impact. Oatly depends on five suppliers for the oats it uses, purchasing this ingredient through millers in Sweden, Denmark, the U.S. and Belgium.\"We have in the past experienced interruptions in the supply of oats from one supplier that resulted in delays in delivery to us,\" the company said, noting that its oat supply is also vulnerable to natural disasters such as drought or floods.\"We could experience similar delays in the future from any of these suppliers.\"The company also depends on select suppliers for enzymes, including one supplier that provides an enzyme for some of Oatly's products, including Barista Edition oat milk.The main components of the company's products are manufactured in four primary facilities as of March 2021, which could also be a problem if something significant happens at any one facility.The dairy market is highly competitive. Oatly identifies conventional dairy companies, including Dean Foods Inc. (DFODQ) and Lactalis as competitors, as well as the growing array of plant-based dairy alternative companies that are entering the market, including soy, almond, hemp and cashew milk brands.All of these companies are competing for a finite number of retail stores, coffee shops, foodservice clients and consumers.\"In order for us to not only maintain our market position, but also to continue to grow and acquire more consumers, some of which may be switching from traditional dairy to plant-based alternatives, we must continue to provide delicious, high-quality products, and consumers must believe in our vision for a food system that is better for people and the planet,\" the company said.Oatly's marketing and COVID-19 might be a hurdle to growth. Oatly says that its history of \"provocative and unconventional marketing and advertising campaigns\" has gotten them into hot water, including a 2014 lawsuit filed by the Swedish dairy lobby in which the courts found Oatly was \"disparaging to dairy products.\"\"The decision resulted in a ban on our further use of a number of expressions marketing our products in Sweden, under the penalty of liquidated damages of SEK 2 million per expression,\" the prospectus said.The company cautions that future marketing could drive other legal action.More recently, Oatly's Super Bowl ad made headlines , but mostly for provoking laughter.","news_type":1,"symbols_score_info":{"OTLY":0.9,"SBUX":0.9}},"isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354946884,"gmtCreate":1617122596648,"gmtModify":1634522521026,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy Buy buy","listText":"Buy Buy buy","text":"Buy Buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/354946884","repostId":"2123291766","repostType":4,"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":"1165830356","repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://ttm.financial/m/news/1165830356?lang=&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 22:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":1874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447407,"gmtCreate":1636024166653,"gmtModify":1636024166821,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447407","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://ttm.financial/m/news/1101079537?lang=&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p>\n<ul>\n <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li>\n</ul>\n<ul>\n <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p>\n<p><i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p>\n<p><i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p>\n<p><i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p>\n<p><i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p>\n<p><i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p>\n<p><i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p>\n<p><b>Updates and recent progress include:</b></p>\n<p><i>COVID-19 Vaccine Development</i></p>\n<ul>\n <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>\n <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>\n <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>\n <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li>\n</ul>\n<p><i>Respiratory Vaccines</i></p>\n<ul>\n <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>\n <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>\n <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li>\n</ul>\n<p><i>Latent Vaccines</i></p>\n<ul>\n <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>\n <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>\n <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li>\n</ul>\n<p><i>Therapeutics</i></p>\n<ul>\n <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>\n <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>\n <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>\n <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>\n <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>\n <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li>\n</ul>\n<p>Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p>\n<p><b>2021 Updated Financial Framework</b></p>\n<ul>\n <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>\n <li></li>\n <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>\n <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>\n <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>\n <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>\n <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>\n <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li>\n</ul>\n<p><b>2022 Revenue Drivers</b></p>\n<p>They expect several dynamics will drive 2022 revenues:</p>\n<ul>\n <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>\n <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>\n <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li>\n</ul>\n<p>Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":117506278,"gmtCreate":1623147977094,"gmtModify":1634036453521,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/117506278","repostId":"1136550999","repostType":4,"repost":{"id":"1136550999","kind":"news","pubTimestamp":1623142939,"share":"https://ttm.financial/m/news/1136550999?lang=&edition=full","pubTime":"2021-06-08 17:02","market":"us","language":"en","title":"Biden administration announces plans to strengthen critical supply chains","url":"https://stock-news.laohu8.com/highlight/detail?id=1136550999","media":"cnbc","summary":"KEY POINTS\n\nThe Biden administration will announce new actions designed to strengthen critical U.S. ","content":"<div>\n<p>KEY POINTS\n\nThe Biden administration will announce new actions designed to strengthen critical U.S. supply chains on Tuesday.\nThey include plans to develop a domestic lithium battery manufacturing ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biden-administration-announces-plans-to-strengthen-critical-supply-chains.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden administration announces plans to strengthen critical supply chains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden administration announces plans to strengthen critical supply chains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biden-administration-announces-plans-to-strengthen-critical-supply-chains.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nThe Biden administration will announce new actions designed to strengthen critical U.S. supply chains on Tuesday.\nThey include plans to develop a domestic lithium battery manufacturing ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biden-administration-announces-plans-to-strengthen-critical-supply-chains.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.cnbc.com/2021/06/08/biden-administration-announces-plans-to-strengthen-critical-supply-chains.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136550999","content_text":"KEY POINTS\n\nThe Biden administration will announce new actions designed to strengthen critical U.S. supply chains on Tuesday.\nThey include plans to develop a domestic lithium battery manufacturing industry, as well as to mine and process rare earth minerals.\nThey also include a USTR “strike force” to combat “unfair foreign trade practices” which the White House says have contributed to the erosion of supply chains around the world.\n\nWASHINGTON — The Biden administration is set to announce a series of steps designed to strengthen critical U.S. supply chains on Tuesday, building up domestic manufacturing capabilities for key products and addressing existing vulnerabilities.\nIn February, President Joe Biden ordered a 100-day interagency review of domestic supply chains.\nThe outcome of this review and the resulting policy recommendations make up a new report totaling several hundred pages,due to bereleased on Tuesday.\nThe report's initial recommendations focus on four products critical to the U.S. economy: large capacity lithium batteries, rare earth minerals, semiconductors and active pharmaceutical ingredients.\n\nLarge capacity lithium batteries:The Department of Energy is aiming to release a 10-year plan to develop a domesticlithium battery supply chain in the United Statescapable of producing the batteries that power electric vehicles. The agency's Advanced Technology Vehicles Manufacturing Loan Program will distribute $17 billion in an effort to support new research and manufacturing efforts in the United States.\nRare earth minerals:The Department of Interior will lead a task force to identify sites wherecritical minerals could be producedand processed in the United States.\" The report said the U.S. will develop the capacity for \"sustainable production, refining, and recycling\" of the 17 rare earth metals used in cell phones, cars and magnets, while meeting high environmental standards.\nSemiconductors:As the nation grapples witha semiconductor shortage that has idled major auto manufacturing plants, the White House said it will work with the private sector to increase supply chain transparency.\nAdvanced pharmaceutical ingredients:The Department of Health and Human Services will use authority granted under the Defense Production Act to commit approximately $60 million to \"develop novel platform technologies to increase domestic manufacturing capacity for API.\"\n\nIn addition to these steps, designed to boost supplies of specific products, the administration also announced several broader initiatives.\nTo help train the workers that will be needed to staff these new projects, the White House will announce $100 million in additional grants to support state-led apprenticeship expansion efforts. The grants will be administered by the Department of Labor.\nThe Department of Energy will announce a new policy that requires awardees of DOE research and development grants to \"substantially manufacture those products in the United States.\"\nAlong with these efforts to bolster domestic supply chains, the Biden administration will also announce new steps to combat \"unfair foreign trade practices,\" which it says have contributed to the erosion of supply chains around the world.\nOne of these will be the creation of a \"trade strike force\" led by the U.S. Trade Representative's office. The strike force will aim to identify \"unilateral and multilateral\" enforcement actions the United States can take to punish countries that it believes are engaging in unfair trade practices. According to a senior administration official, the strike force will focus on developing U.S.-China trade policies.\nThe other enforcement-related action will be an evaluation, led by the Department of Commerce, of whether to initiate an investigation into neodymium magnets under Section 232 of the Trade Expansion Act.\nThe rare earth magnets are used in motors and electronics by both civilians and the military. If the investigation were to conclude that U.S. national security is threatened by foreign supplies of neodymium, it could open the door to import restrictions or tariffs.\nBiden's predecessor, Donald Trump, invoked Section 232 twice during his one term as president, citing it as his justification for imposing broad steel and aluminum tariffs. Those tariffs are still in place, and Biden has not said whether he will lift them or not.\nA senior administration official who briefed reporters emphasized that Biden's trade policy actions are fundamentally different from Trump's trade wars, because they are carefully targeted.\n\"We're not looking to wage trade wars with our allies and partners,\" said the official. \"We're looking at very targeted products where we think there are effective tools we could deploy to strengthen our own supply chains and reduce vulnerabilities.\"","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347687423,"gmtCreate":1618493700662,"gmtModify":1634292571818,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347687423","repostId":"1148801353","repostType":4,"repost":{"id":"1148801353","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618493511,"share":"https://ttm.financial/m/news/1148801353?lang=&edition=full","pubTime":"2021-04-15 21:31","market":"us","language":"en","title":"Stocks jump at the open as Coinbase rises, Americans go shopping","url":"https://stock-news.laohu8.com/highlight/detail?id=1148801353","media":"Tiger Newspress","summary":"(April 15) U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate r","content":"<p>(April 15)&nbsp;U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.</p><p>The Dow Jones Industrial Average&nbsp;added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&amp;P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index&nbsp;was up 122 points or 0.9%, near 13,980.</p><p>First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.</p><p>Shares of Coinbase Global Inc.&nbsp;gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc.&nbsp;beat analyst expectations.</p><p>A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.</p><p>Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.</p><p>Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.</p><p>Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.</p><p>On Tuesday, the Food and Drug Administration called for a pause&nbsp;in administering J&amp;J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks jump at the open as Coinbase rises, Americans go shopping</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks jump at the open as Coinbase rises, Americans go shopping\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-15 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 15)&nbsp;U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.</p><p>The Dow Jones Industrial Average&nbsp;added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&amp;P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index&nbsp;was up 122 points or 0.9%, near 13,980.</p><p>First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.</p><p>Shares of Coinbase Global Inc.&nbsp;gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc.&nbsp;beat analyst expectations.</p><p>A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.</p><p>Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.</p><p>Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.</p><p>Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.</p><p>On Tuesday, the Food and Drug Administration called for a pause&nbsp;in administering J&amp;J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148801353","content_text":"(April 15) U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.The Dow Jones Industrial Average added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index was up 122 points or 0.9%, near 13,980.First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.Shares of Coinbase Global Inc. gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc. beat analyst expectations.A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.On Tuesday, the Food and Drug Administration called for a pause in administering J&J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608690847,"gmtCreate":1638701123059,"gmtModify":1638701123059,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608690847","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","kind":"highlight","pubTimestamp":1638543717,"share":"https://ttm.financial/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b>&nbsp;or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4538":"云计算","BK4504":"桥水持仓","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","BK4507":"流媒体概念","BAC":"美国银行","BRK.B":"伯克希尔B","BK4548":"巴美列捷福持仓","BK4007":"制药","BK4551":"寇图资本持仓","BRK.A":"伯克希尔","BK4207":"综合性银行","BMY":"施贵宝","BK4561":"索罗斯持仓","BK4524":"宅经济概念","BK4557":"大麻股","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4527":"明星科技股","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4106":"数据处理与外包服务","AMZN":"亚马逊","BK4503":"景林资产持仓","V":"Visa","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4122":"互联网与直销零售","BK4176":"多领域控股","BK4566":"资本集团","BK4535":"淡马锡持仓"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1,"symbols_score_info":{"AMZN":0.9,"BAC":0.9,"BMY":0.9,"BRK.A":0.9,"BRK.B":0.9,"TEVA":0.9,"V":0.9}},"isVote":1,"tweetType":1,"viewCount":2467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}